<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-132252" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Interstitial Cystitis/Bladder Pain Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lim</surname>
            <given-names>Yizhe</given-names>
          </name>
          <aff>Torbay Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>O'Rourke</surname>
            <given-names>Seanan</given-names>
          </name>
          <aff>University College Dublin</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yizhe Lim declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Seanan O'Rourke declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-132252.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Interstitial cystitis/bladder pain syndrome is a complex and chronic medical condition that primarily affects the urinary bladder, leading to a range of distressing symptoms. This disorder is characterized by the inflammation of the bladder's lining, resulting in recurring and often severe discomfort, urgency, and frequency of urination. Interstitial cystitis remains challenging to diagnose and manage, as its precise causes are not fully understood, and it can mimic other urinary tract disorders. Individuals living with interstitial cystitis face a significant impact on their quality of life, as the symptoms can be disruptive and emotionally taxing. Patients' responses to treatment are highly variable. This activity reviews the approach, investigation, and management of interstitial cystitis/bladder pain syndrome and highlights the role of the interprofessional team in evaluating and treating this challenging disorder.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the multifaceted etiology of interstitial cystitis/bladder pain syndrome.</p></list-item><list-item><p>Implement evidence-based treatment plans, integrating the latest therapeutic options and guidelines, tailored to patients' specific needs and severity of interstitial cystitis/bladder pain syndrome.</p></list-item><list-item><p>Apply a multidisciplinary approach to assessing&#x000a0;the prognosis of interstitial cystitis/bladder pain syndrome.</p></list-item><list-item><p>Collaborate with an interprofessional team to create a coordinated and comprehensive care plan for patients with interstitial cystitis/bladder pain syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132252&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132252">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-132252.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Interstitial cystitis/bladder pain syndrome (IC/BPS), formerly called interstitial cystitis, is a chronic (&#x0003e;6 weeks duration) pelvic condition that affects or appears to affect the urinary bladder with symptoms of discomfort, pressure, or pain.&#x000a0;The condition is characterized by chronic inflammation and lower urinary tract symptoms, not due to infection or any other clearly identifiable cause.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r2">[2]</xref>&#x000a0;As the definition varies somewhat between different societies and organizations, we will use the American Urological Association (AUA) definition.&#x000a0;</p>
        <p>In many cases, because IC/BPS remains a diagnosis of exclusion, the condition is often identified late or misdiagnosed, particularly in men, as chronic prostatitis/chronic pelvic pain syndrome or overactive bladder.<xref ref-type="bibr" rid="article-132252.r3">[3]</xref><xref ref-type="bibr" rid="article-132252.r4">[4]</xref><xref ref-type="bibr" rid="article-132252.r5">[5]</xref><xref ref-type="bibr" rid="article-132252.r6">[6]</xref><xref ref-type="bibr" rid="article-132252.r7">[7]</xref></p>
        <p>Patients often describe pain in the bladder or suprapubic region, with an intense sensation of urinary urgency. This sensation is worsened by bladder filling but is temporarily relieved by passing urine, which typically results in severe urinary frequency. This may be during the daytime and/or overnight. The urinary frequency is generally refractory to standard overactive bladder therapy, which should suggest considering a diagnosis of IC/BPS.</p>
        <p>There may also be other symptoms, such as pain or burning when passing urine (dysuria) and discomfort during sexual intercourse, causing dyspareunia in women and ejaculatory pain in men. These chronic symptoms profoundly impact the patient's emotional, psychological, and social well-being as well as their quality of life.<xref ref-type="bibr" rid="article-132252.r8">[8]</xref></p>
        <p>
<bold>Anatomy</bold>
</p>
        <p>The urinary bladder is a hollow viscus organ located in the pelvis, anterior to the rectum in both sexes and the uterus in females. It is partially covered by the peritoneum on the superior surface. It is composed of&#x000a0;4 layers.<xref ref-type="bibr" rid="article-132252.r9">[9]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The mucosa, which contains the transitional epithelium, is the bladder lining and allows for the stretch of the urinary bladder. When stretched, the surface is smooth, but when relaxed, folds form in the mucosa, known as rugae.&#x000a0;The mucosa also produces glycosaminoglycans (GAGs), making up the superficial coating that protects the mucosa from direct contact with potentially inflammatory urinary irritants.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The submucosa is composed of elastic connective tissue and further assists with the stretch of the bladder.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The muscularis layer (detrusor muscle) is composed of several layers (inner longitudinal, middle circular, and outer longitudinal) of smooth muscle oriented in multiple directions, which produce a uniform, simultaneous contraction that efficiently empties the bladder when a contraction is triggered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The muscles also form a small band that encircles the area between the opening of the bladder and the urethra. This is known as the internal urinary sphincter and is controlled by the autonomic nervous system. Another distal band around the urethra controls conscious voiding, called the external sphincter, composed of skeletal muscle and innervated by the somatic nervous system.<xref ref-type="bibr" rid="article-132252.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In women, the external urethral sphincter is distal and inferior to the bladder neck. The clitoris and pubic bone are anterior, while the anterior vaginal roof is immediately posterior.&#x000a0;The external sphincter in women is also known as the urogenital sphincter.<xref ref-type="bibr" rid="article-132252.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The fibrous connective tissue layer is the outermost covering of the bladder, except for the superior surface, which is covered by the parietal peritoneum.<xref ref-type="bibr" rid="article-132252.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>The bladder floor also contains a fixed, triangular area called the trigone. The openings to each ureter and the outlet to the urethra form the trigone. There are 3 apices, with a ureteral orifice in each lateral wing and the third arm entering the urethra.<xref ref-type="bibr" rid="article-132252.r11">[11]</xref>&#x000a0;The trigone is located at the posterior base, also known as the fundus of the urinary bladder.<xref ref-type="bibr" rid="article-132252.r12">[12]</xref></p>
        <p>The distal intramural portion of each ureter follows a shallow submucosal course as it travels through the detrusor muscle into the bladder. This anatomy acts as an anti-reflux mechanism or valve to prevent urine reflux into the kidney.&#x000a0;</p>
      </sec>
      <sec id="article-132252.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of&#x000a0;IC/BPS is not well understood, and the current thoughts around its pathogenesis remain multifactorial.&#x000a0;</p>
        <p>Current research strongly suggests&#x000a0;an underlying inflammatory process, although the precise cause for this is not well-understood.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref>&#x000a0;</p>
        <p>Cystoscopy findings in individuals with normal bladder function&#x000a0;are characterized by a pale/pink mucosal appearance, a lack of erythema and swellings, and relatively straight capillaries (see <bold>Image.&#x000a0;</bold>Normal Mucosa of the Bladder Wall).&#x000a0;Cystoscopy in IC/BPS patients typically shows submucosal inflammation, which is seen as glomerulations (see<bold> Image.&#x000a0;</bold>Abnormal Mucosa Wall).&#x000a0;Large groups of mast cells are frequently found, further stimulating afferent sensory fibers. Increased urothelial permeability due to diminished GAG levels and ultrastructural abnormalities are seen on biopsies with a loss of tight junctions and adhesive junction proteins. This causes a loss of mucosal barrier protection, resulting in a "leaky urothelium." This is also thought to be the reason why immunoglobulin and immune mediators are detected at higher levels in the urine of affected individuals.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref><xref ref-type="bibr" rid="article-132252.r14">[14]</xref><xref ref-type="bibr" rid="article-132252.r15">[15]</xref></p>
        <p>Fibrosis also results from the chronic inflammatory process, evident by the upregulation of extracellular matrix proteins, increased myofibroblasts, and decreased capillary density, which reduce bladder capacity and lead to further stretching and stimulation of afferent sensory pain fibers.<xref ref-type="bibr" rid="article-132252.r16">[16]</xref></p>
        <p>Increased grey matter volume has been found in some IC/BPS patients with the disorder in brain regions responsible for pain perception. This was observed using functional magnetic resonance imaging (fMRI).<xref ref-type="bibr" rid="article-132252.r17">[17]</xref><xref ref-type="bibr" rid="article-132252.r18">[18]</xref></p>
        <p>Severe IC-like symptoms can develop after the use of illegally sourced ketamine. The precise etiology of this response remains unknown. The main theories involve urothelial damage, microvascular changes, autoimmunity, and infection either by ketamine or metabolites. The symptoms, cystoscopy, and biopsy findings have a great degree of crossover with IC, and the main difference would be the recreational abuse of ketamine. The risk of developing ketamine cystitis does not appear to be increased with the proper medical use of the drug.<xref ref-type="bibr" rid="article-132252.r19">[19]</xref></p>
        <p>Leading concepts regarding the underlying etiology of IC/BPS include the following:&#x000a0;<xref ref-type="bibr" rid="article-132252.r20">[20]</xref><xref ref-type="bibr" rid="article-132252.r21">[21]</xref><xref ref-type="bibr" rid="article-132252.r22">[22]</xref><xref ref-type="bibr" rid="article-132252.r23">[23]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Autoimmune or immune-mediated processes</p>
          </list-item>
          <list-item>
            <p>Chronic inflammation</p>
          </list-item>
          <list-item>
            <p>Chronic stress</p>
          </list-item>
          <list-item>
            <p>Fibrosis</p>
          </list-item>
          <list-item>
            <p>Heightened pain sensitivity&#x000a0;due to an increase in grey matter volume</p>
          </list-item>
          <list-item>
            <p>Mast cell dysfunction or hyperactivation</p>
          </list-item>
          <list-item>
            <p>Neurogenic inflammation/edema</p>
          </list-item>
          <list-item>
            <p>Pelvic floor hypertonicity or dysfunction</p>
          </list-item>
          <list-item>
            <p>Upregulation and proliferation of sensory afferent fibers</p>
          </list-item>
          <list-item>
            <p>Urothelial dysfunction and exposure, especially in the epithelial and glycosaminoglycans (GAGs) layer</p>
          </list-item>
          <list-item>
            <p>Vascular malformations that are seen as glomerulations on cystoscopy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132252.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Due to the nature of IC/BPS, it is very difficult to formulate a clear early diagnosis, and no accepted screening tool exists. Therefore, the data surrounding its prevalence remains limited.&#x000a0;</p>
        <p>Some studies have specifically looked into the epidemiology of IC/BPS. There are&#x000a0;2 main study designs, one using physician/urologist-based diagnosis and the other using a patient questionnaire involving symptomatology.&#x000a0;A lower prevalence is seen when physician-completed questionnaires and histological samples were employed to establish a diagnosis.</p>
        <list list-type="bullet">
          <list-item>
            <p>Based on a large population, questionnaire-based prevalence study in the US, 2.7% of women and 1.9% of men met the specified criteria.<xref ref-type="bibr" rid="article-132252.r24">[24]</xref><xref ref-type="bibr" rid="article-132252.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other studies have estimated the prevalence at &#x0003e;6% with a higher incidence in women.<xref ref-type="bibr" rid="article-132252.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In terms of age groups, the most common prevalence was in women between 50 to 59 years of age and men between 56&#x000a0;to 74 years of age.<xref ref-type="bibr" rid="article-132252.r24">[24]</xref><xref ref-type="bibr" rid="article-132252.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IC/BPS&#x000a0;has an estimated prevalence of 3&#x000a0;million to 8 million women and 1 million to 4 million men in the US.<xref ref-type="bibr" rid="article-132252.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The number of men affected is probably underestimated, as many are misdiagnosed as having chronic prostatitis.<xref ref-type="bibr" rid="article-132252.r3">[3]</xref><xref ref-type="bibr" rid="article-132252.r4">[4]</xref><xref ref-type="bibr" rid="article-132252.r5">[5]</xref><xref ref-type="bibr" rid="article-132252.r6">[6]</xref><xref ref-type="bibr" rid="article-132252.r7">[7]</xref><xref ref-type="bibr" rid="article-132252.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Investigations&#x000a0;have noted a female predisposition, with&#x000a0;1 study in the US finding a 5&#x000a0;to 1 ratio.<xref ref-type="bibr" rid="article-132252.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A study in the Netherlands quoted a prevalence as low as 8 to 16 out of 100,000 individuals.<xref ref-type="bibr" rid="article-132252.r29">[29]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>It is estimated that&#x000a0;IC/BPS affects up to 400,000 patients in the UK, with almost 90% being women between 50 to 69 years of age.<xref ref-type="bibr" rid="article-132252.r30">[30]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The data for children affected by&#x000a0;IC/BPS&#x000a0;is poor, but the consensus is that the prevalence is very low in the pediatric population.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132252.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The underlying pathophysiology of IC/BPS is somewhat uncertain, contributing to the lack of a definitive, curative remedy.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref> Known involved bladder pathological findings include chronic inflammation, afferent sensory hyperactivity, nociceptor upregulation, mast cell overactivity, submucosal microvascular abnormalities, autoimmune disorders, lack of normal bladder epithelial cell growth, and urothelial thinning with a deficient or dysfunctional superficial mucosal&#x000a0;GAGs layer.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref><xref ref-type="bibr" rid="article-132252.r14">[14]</xref><xref ref-type="bibr" rid="article-132252.r22">[22]</xref><xref ref-type="bibr" rid="article-132252.r31">[31]</xref><xref ref-type="bibr" rid="article-132252.r32">[32]</xref><xref ref-type="bibr" rid="article-132252.r33">[33]</xref>&#x000a0;</p>
        <p>Other findings associated with chronic bladder inflammation include decreased mucosal protection from GAGs loss or dysfunction, lower adhesive protein E-cadherin, decreased basal cell growth, defective umbrella cell integrity, abnormal apical cell maturation, and increased urothelial cell apoptosis.<xref ref-type="bibr" rid="article-132252.r31">[31]</xref><xref ref-type="bibr" rid="article-132252.r34">[34]</xref>&#x000a0;The increased serum levels of C-reactive protein and pro-inflammatory cytokines also point to inflammation as a primary underlying etiology of IC/BPS.<xref ref-type="bibr" rid="article-132252.r14">[14]</xref><xref ref-type="bibr" rid="article-132252.r15">[15]</xref>&#x000a0;Tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) and nerve growth factor (NGF) are also increased in IC/BPS patients.<xref ref-type="bibr" rid="article-132252.r35">[35]</xref></p>
        <p>IC/BPS&#x000a0;can appear as two separate&#x000a0;entities: the&#x000a0;IC entity clearly demonstrates an inflammatory component that is mostly missing in those with the predominantly BPS entity.<xref ref-type="bibr" rid="article-132252.r36">[36]</xref>&#x000a0;</p>
        <p>IC/BPS&#x000a0;patients are much more likely than the general population to have systemic lupus erythematosus.<xref ref-type="bibr" rid="article-132252.r37">[37]</xref>&#x000a0;There is also a close association with Hashimoto's thyroiditis, rheumatoid arthritis, ankylosing spondylitis, irritable bowel syndrome, fibromyalgia, chronic fatigue, and especially Sjogren syndrome.<xref ref-type="bibr" rid="article-132252.r38">[38]</xref><xref ref-type="bibr" rid="article-132252.r39">[39]</xref><xref ref-type="bibr" rid="article-132252.r40">[40]</xref>&#x000a0;This suggests an autoimmune component, possibly an autoantibody to M3 receptors in the bladder, at least in some patients.<xref ref-type="bibr" rid="article-132252.r41">[41]</xref></p>
        <p>Chronic stress is found in &#x0003e;50% of IC/BPS patients, which is a factor in the development and exacerbation of symptoms.<xref ref-type="bibr" rid="article-132252.r36">[36]</xref><xref ref-type="bibr" rid="article-132252.r42">[42]</xref><xref ref-type="bibr" rid="article-132252.r43">[43]</xref><xref ref-type="bibr" rid="article-132252.r44">[44]</xref><xref ref-type="bibr" rid="article-132252.r45">[45]</xref><xref ref-type="bibr" rid="article-132252.r46">[46]</xref></p>
        <p>The chronic pain typically associated with IC/BPS is caused by sensory afferent nerve activity and central nervous system sensitization.<xref ref-type="bibr" rid="article-132252.r47">[47]</xref></p>
      </sec>
      <sec id="article-132252.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologically, no specific pathognomonic finding is diagnostic for IC/BPS.<xref ref-type="bibr" rid="article-132252.r48">[48]</xref>&#x000a0;However, compared to a similar control group, IC/BPS patients demonstrated a higher frequency and severity of bladder mucosal ulcerations with denuded superficial urothelium, submucosal inflammation of the lamina propria, and lymphocytic inflammatory infiltrate with mast cell accumulations in the lamina propria and detrusor.<xref ref-type="bibr" rid="article-132252.r49">[49]</xref><xref ref-type="bibr" rid="article-132252.r50">[50]</xref>&#x000a0;While interesting, these findings are insufficient to be of any diagnostic help except to exclude malignancy and other pathologies.<xref ref-type="bibr" rid="article-132252.r48">[48]</xref><xref ref-type="bibr" rid="article-132252.r51">[51]</xref></p>
        <p>Urothelial defects, as seen on electron microscopy, appear to correlate well with symptom severity in patients with IC, which suggests a causal relationship.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-132252.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Symptoms must&#x000a0;last at least 6 weeks with negative urine cultures&#x000a0;and no acceptable explanation or alternative diagnosis.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;Typical symptoms involve urinary frequency, nocturia, and suprapubic pain, which persist even after voiding. There may be urgency, nocturia, or dysuria, but usually no incontinence.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;IC/BPS pain is usually suprapubic but may also be perineal. The discomfort is typically improved but not totally relieved by voiding.&#x000a0;Incontinence&#x000a0;is not a typical symptom of IC/BPS.</p>
        <p>A&#x000a0;baseline record of the patient's symptoms is useful to compare treatment efficacy. This may be a recommended pain scale index, a visual chart, or a patient-recorded 24-hour voiding diary.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref></p>
        <p>Pain can be evaluated and recorded using the&#x000a0;IC symptoms index (ICSI), a visual analog chart, or the genitourinary pain index (GUPI).<xref ref-type="bibr" rid="article-132252.r52">[52]</xref><xref ref-type="bibr" rid="article-132252.r53">[53]</xref></p>
        <p>Voided volumes and a 24-hour timed voiding diary document the degree and severity of the patient's urinary frequency symptoms.<xref ref-type="bibr" rid="article-132252.r54">[54]</xref><xref ref-type="bibr" rid="article-132252.r55">[55]</xref><xref ref-type="bibr" rid="article-132252.r56">[56]</xref></p>
        <p>Symptoms typically have periodic flares or exacerbations and remissions. As a complete remission is uncommon, over the long course of the disorder, patients often become anxious, depressed, and/or have difficulty sleeping.<xref ref-type="bibr" rid="article-132252.r57">[57]</xref></p>
        <p>IC/BPS should be considered in all patients originally diagnosed with overactive bladder who do not improve on standard therapy.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref></p>
        <p>Unusually high voided volumes or infrequent voiding would suggest an alternative diagnosis.</p>
        <p>Urinary and related symptoms to record and document include the following:&#x000a0;<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Number of voids per day</p>
          </list-item>
          <list-item>
            <p>Urine volume per voiding episode</p>
          </list-item>
          <list-item>
            <p>Episodes of incontinence</p>
          </list-item>
          <list-item>
            <p>Episodes of urgency</p>
          </list-item>
          <list-item>
            <p>Hematuria</p>
          </list-item>
          <list-item>
            <p>Details and characteristics of pain:
<list list-type="bullet"><list-item><p>Character</p></list-item><list-item><p>Duration</p></list-item><list-item><p>Dyspareunia (present or not) in women</p></list-item><list-item><p>Dysuria (present or not)</p></list-item><list-item><p>Ejaculatory dysfunction or pain (present or not) in men</p></list-item><list-item><p>Location</p></list-item><list-item><p>Pain relieved by voiding (present or not)</p></list-item><list-item><p>Pressure or urge to void</p></list-item><list-item><p>Relationship of pain to menstruation, food, or any other activity</p></list-item><list-item><p>Severity (as well as any concomitant dysuria) should be recorded for at least 24 hours</p></list-item><list-item><p>Time</p></list-item><list-item><p>Unexplained fevers</p></list-item><list-item><p>Vulvar pain</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>All patients suspected of having IC/BPS should have a neurological examination performed, including tone, reflexes, power, sensation, and cranial nerve testing.&#x000a0;A post-void residual urine volume determination should be completed.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r54">[54]</xref></p>
        <p>A detailed gynecological history and pelvic examination should be performed on all female patients suspected of having IC/BPS.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0; Careful attention should be paid to cervical tenderness, masses, prolapse, and abnormalities found on adnexal palpation.</p>
        <p>An appropriate hematuria evaluation should be performed in patients with unexplained or previously unevaluated urinary blood and those with symptoms of IC/BPS who also have a significant (&#x02265;10 pack-years) smoking history.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r58">[58]</xref></p>
        <p>A detailed history and careful examination are needed to exclude other causes, as there is considerable overlap between IC/BPS and other conditions.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r8">[8]</xref></p>
        <p>
<bold>Interstitial Cystitis/Bladder Pain Syndrome and Chronic Prostatitis/Chronic Pelvic Pain Syndrome&#x000a0;</bold>
</p>
        <p>Many experts believe that chronic prostatitis in men may often be misdiagnosed as IC, which may be the more common disorder even in males.<xref ref-type="bibr" rid="article-132252.r3">[3]</xref><xref ref-type="bibr" rid="article-132252.r4">[4]</xref><xref ref-type="bibr" rid="article-132252.r5">[5]</xref><xref ref-type="bibr" rid="article-132252.r6">[6]</xref><xref ref-type="bibr" rid="article-132252.r7">[7]</xref>&#x000a0;The primary differences are the lack of the urinary antiproliferative factor and histological bladder pathology&#x000a0;in chronic prostatitis.<xref ref-type="bibr" rid="article-132252.r59">[59]</xref>&#x000a0;The&#x000a0;2 conditions have many similarities as both demonstrate the following:<xref ref-type="bibr" rid="article-132252.r3">[3]</xref><xref ref-type="bibr" rid="article-132252.r4">[4]</xref><xref ref-type="bibr" rid="article-132252.r6">[6]</xref><xref ref-type="bibr" rid="article-132252.r7">[7]</xref><xref ref-type="bibr" rid="article-132252.r60">[60]</xref><xref ref-type="bibr" rid="article-132252.r61">[61]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Associated with psychosocial depression</p>
          </list-item>
          <list-item>
            <p>Characterized by chronic pelvic pain and urinary symptoms, usually urgency and frequency but not incontinence</p>
          </list-item>
          <list-item>
            <p>Diagnosis is primarily by exclusion</p>
          </list-item>
          <list-item>
            <p>Dietary changes often have a significant impact on the disorder</p>
          </list-item>
          <list-item>
            <p>Negative urine cultures</p>
          </list-item>
          <list-item>
            <p>Oral medications can offer symptomatic relief</p>
          </list-item>
          <list-item>
            <p>Pelvic floor dysfunction</p>
          </list-item>
          <list-item>
            <p>Physical therapy provides relief for the majority of patients</p>
          </list-item>
          <list-item>
            <p>Sensitivity to intravesical potassium instillation</p>
          </list-item>
          <list-item>
            <p>Symptoms are aggravated by the same foods and dietary irritants</p>
          </list-item>
          <list-item>
            <p>Symptoms may last for years</p>
          </list-item>
        </list>
        <p>Men with&#x000a0;IC/BPS or chronic prostatitis/chronic pelvic pain syndrome tend to have a higher incidence of erectile and ejaculatory dysfunction than&#x000a0;unaffected males and are more likely to be associated with depression, pain, and stress.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="37057400">[62]</ext-link>&#x000a0;Over 70% of men with&#x000a0;IC/BPS report sexual dysfunction.<xref ref-type="bibr" rid="article-132252.r62">[63]</xref></p>
        <p>Patients with IC/BPS who have not responded to standard therapy might have chronic prostatitis/chronic pelvic pain syndrome, and consideration should be given to a change in therapy. Likewise, patients with chronic prostatitis who have not responded to conservative treatment should be evaluated for possible IC/BPS.</p>
        <p><bold>Pudendal neuralgia</bold>&#x000a0;can mimic IC/BPS in many ways. Common symptoms include chronic pelvic pain, sexual dysfunction, discomfort with sexual activity, and urinary dysfunction.&#x000a0;Pudendal neuralgia patients often have very tight, dysfunctional pelvic floor musculature, but so can patients with IC/BPS.<xref ref-type="bibr" rid="article-132252.r63">[64]</xref></p>
        <p>Patients with pudendal neuralgia tend to describe the pain as more intense and having a "burning" or "electrical shock" feeling.&#x000a0;The pain is associated with sitting, bending, or squatting and is generally unrelated to bladder fullness or diet. They also tend not to have the degree of urinary frequency and urgency associated with IC/BPS. If in doubt, pudendal nerve blocks can be both diagnostic and potentially therapeutic, particularly in patients unresponsive to standard therapies for IC/BPS where pudendal neuralgia might be possible.<xref ref-type="bibr" rid="article-132252.r63">[64]</xref></p>
      </sec>
      <sec id="article-132252.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The workup should include laboratory examinations and procedures to identify other disorders that can produce symptoms similar to IC/BPS. This typically includes standard blood tests (CBC, CMP, glucose, HbA1c), urinalyses (microscopic) and urine cultures, and appropriate sexual health screening, including testing for&#x000a0;sexually transmitted infections as appropriate.&#x000a0;</p>
        <p>Urine cultures in patients with negative urinalysis are suggested to identify low or borderline bacteria levels that may still be clinically significant but escape detection on standard examinations.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref></p>
        <p>Neither cystoscopy nor urodynamics is required to diagnose IC/BPS according to the AUA guidelines.&#x000a0;Neither is diagnostic, but they may be appropriate if the diagnosis is in doubt.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref></p>
        <p>IC/BPS patients with Hunner ulcers tend to be older with higher symptom scores, increased urinary frequency, more nocturia episodes, smaller voided volumes, and a reduced bladder capacity with hydrodistension than IC/BPS patients without Hunner lesions.<xref ref-type="bibr" rid="article-132252.r64">[65]</xref>&#x000a0;They were also more likely to have an autoimmune disorder comorbidity.</p>
        <p>A number of urinary inflammatory biomarkers are increased in IC/BPS, such as&#x000a0;TNF-&#x003b1;, PGE2, IL-2, IL-6, IL-8, IP10, TAC, and 8-OHdG, although the diagnostic and clinical utility of this finding still needs to be determined.<xref ref-type="bibr" rid="article-132252.r35">[35]</xref><xref ref-type="bibr" rid="article-132252.r65">[66]</xref>&#x000a0;A recent study of urinary biomarkers in 191 pateints suggested that&#x000a0;TNF-&#x003b1;, IP-10, TAC, 8-OHdG, and IL-2 could be useful in differentiating interstitial cystitis from other urinary disorders.<xref ref-type="bibr" rid="article-132252.r65">[66]</xref>&#x000a0;While promising, a definitive, clinically useful urinary cytokine or combination of biomarkers is still to be determined.<xref ref-type="bibr" rid="article-132252.r20">[20]</xref><xref ref-type="bibr" rid="article-132252.r65">[66]</xref></p>
        <p><bold>Cystoscopy</bold> is appropriate if there is a suspicion of bladder cancer, intravesical foreign bodies, outlet obstruction, strictures, or vesical calculi. Glomerulations are often found but are considered non-specific. There are no specific cystoscopic findings diagnostic of IC/BPS other than a Hunner ulcer, which is more commonly found in patients over age 50 in whom a cystoscopy may, therefore, be justified.<xref ref-type="bibr" rid="article-132252.r66">[67]</xref>&#x000a0;Patients who fail conventional therapy may also be candidates for a cystoscopy, especially if they have not previously had the procedure, but the examination is generally discouraged in younger patients where Hunner ulcers are far less common, and it is likely to cause more complications and&#x000a0;adverse&#x000a0;effects.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;</p>
        <p>A Hunner ulcer is characteristic and diagnostic of classic IC. It is described as a central scar in an area of erythematous mucosa.<xref ref-type="bibr" rid="article-132252.r67">[68]</xref> Small blood vessels can be seen radiating toward this scar, which will often have a small adherent blood clot.&#x000a0;After hydrodistension, the surrounding mucosa ruptures, resulting in the bleeding typically associated with this pathological lesion.<xref ref-type="bibr" rid="article-132252.r67">[68]</xref>&#x000a0;Since many urologists rarely see a Hunner ulcer, reviewing a published atlas of these clinically important diagnostic lesions may be useful.<xref ref-type="bibr" rid="article-132252.r68">[69]</xref></p>
        <p>Patients with Hunner ulcers generally respond well to treatment. Standard therapy for a Hunner ulcer includes immediate fulguration of the lesion and/or an injection of triamcinolone.<xref ref-type="bibr" rid="article-132252.r69">[70]</xref>&#x000a0;Symptom relief after Hunner ulcer treatment is reportedly as high as 97%.<xref ref-type="bibr" rid="article-132252.r70">[71]</xref>&#x000a0;If this fails, oral cyclosporine A is recommended.<xref ref-type="bibr" rid="article-132252.r71">[72]</xref>&#x000a0;Since the odds of identifying Hunner lesions are markedly reduced in patients younger than 50 years, routine cystoscopic examinations are not recommended or suggested for patients with IC/BPS symptoms in this age group.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;</p>
        <p>Bladder biopsies are not routinely necessary or recommended according to the AUA guidelines unless malignancy is suspected.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;This is based on the relative rarity of bladder cancer in patients diagnosed with IC/BPS (1:600).<xref ref-type="bibr" rid="article-132252.r72">[73]</xref></p>
        <p>However, guidelines from the&#x000a0;European Association of Urology (EAU), the International Society for the Study of BPS (ESSIC), the International&#x000a0;Continence Society (ICS), and the Canadian Urological Association (CUA) recommend hydrodistension with cystoscopic random biopsies due to the substantial overlap in visual appearance and symptoms between IC/BPS and bladder cancer.<xref ref-type="bibr" rid="article-132252.r73">[74]</xref>&#x000a0;In a recent study of 55 IC/BPS patients, 3 (5.5%) were found to have bladder cancer when random biopsies were performed.<xref ref-type="bibr" rid="article-132252.r73">[74]</xref>&#x000a0;It is unknown if urine cytology, FISH testing, or bladder washing would be sufficient to identify these cancers without requiring a more invasive biopsy.</p>
        <p>Cystoscopy primarily rules&#x000a0;out malignancy, strictures, Hunner ulcers, and bladder outlet obstruction.</p>
        <list list-type="bullet">
          <list-item>
            <p>The appearance of bladder lesions can be very similar to malignancy, particularly carcinoma-in-situ.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The bladder walls may show scarring or petechial hemorrhages, known as glomerulations, which are considered non-specific.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>During visualization of the distended bladder, there may be Hunner ulcers, often described as pale central scars with or without a fibrin clot and surrounded by erythematous mucosa, with small vessels radiating towards the center (see <bold>Image.</bold> Abnormal Bladder Mucosa, Showing a Hunner Ulcer).&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hunner ulcers are most commonly located at the posterior bladder mucosa (see <bold>Image.</bold> Illustration of the Bladder Anatomy, with an Illustration of a Classic Hunner's Ulcer).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hunner ulcers are considered diagnostic for IC, but they are uncommon and may only be present in 5% to 10% of cases.<xref ref-type="bibr" rid="article-132252.r74">[75]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with Hunner ulcers tend to have the most inflammation and require a more aggressive therapeutic approach.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reactive hemorrhages are also a sign of IC. This is when the mucosa appears normal when distended on an initial examination under cystoscopy, but when deflated and re-inspected, points of capillary bleeding are noted on a background of normal mucosa.<xref ref-type="bibr" rid="article-132252.r75">[76]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Further investigations or treatments may also be performed during a cystoscopy, such as hydrodistention, lidocaine or intravesical cocktail instillation, fulguration and/or triamcinolone injections for Hunner ulcers, or random bladder biopsies.</p>
          </list-item>
        </list>
        <p><bold>Urodynamics</bold> can be helpful when patients are refractory to standard medical treatments or there is evidence of bladder outlet obstruction, detrusor hypotonicity, neurogenic bladder, or other conditions that might otherwise explain the patient's symptoms.&#x000a0;There are no specific urodynamic findings that are diagnostic of IC/BPS. However, a small maximum bladder capacity (&#x0003c;300 mL) is frequently found.&#x000a0;Urodynamic studies are not recommended in routine cases.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-132252.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Before commencing treatment, the American Urological Association (AUA) Guidelines recommend educating the patient about the disease's complex nature and the need for multimodal therapy, as patient&#x000a0;education about IC/BPS is a critical part of the treatment plan.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;An&#x000a0;individualized approach, including shared decision-making for every patient, is suggested.</p>
        <p>For most patients, no single treatment exists to cure the condition or permanently relieve the symptoms. Patients should also be aware that multiple treatment options in combination may be needed for optimal symptom control and that the condition is chronic, often with periodic exacerbations and remissions.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref></p>
        <p>As the underlying pathophysiology is still largely unknown, treatment is based on managing the symptoms.</p>
        <p>Treatment should be evaluated periodically, and ineffective therapies should be discarded. If simple pain management techniques are not adequate, additional therapy should be used, and consideration given to a pain management consultation as a multidisciplinary approach is recommended. Failure of multiple modalities of therapy suggests a possible misdiagnosis.</p>
        <p>
<bold>Conservative Measures</bold>
</p>
        <p>Initial treatment for IC/BPS should be based on dietary and lifestyle modifications. The determination of specific dietary adjustments is based on known common irritants. Elimination diets are used to identify additional exacerbating dietary factors.&#x000a0;The final recommended diet should be individualized, with a diary to record which foods, beverages, additives, or substances cause symptoms to flare.</p>
        <p>Generally, a number of common foods are known to irritate sensitive bladders, cause pain, and exacerbate urinary symptoms. A complete list can be found at the website for the Interstitial Cystitis Association at&#x000a0; www.ichelp.org.The prevailing theory is many foods contain substances or chemicals that are inherently irritating to the bladder, such as a high acid content, potassium, or capsaicin. Indian, Mexican, and Thai food is not recommended. Specific foods known to cause bladder irritation include the following:&#x000a0;<xref ref-type="bibr" rid="article-132252.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Alcohol</p>
          </list-item>
          <list-item>
            <p>Benzyl alcohol</p>
          </list-item>
          <list-item>
            <p>Caffeine</p>
          </list-item>
          <list-item>
            <p>Carbonated beverages</p>
          </list-item>
          <list-item>
            <p>Coffee</p>
          </list-item>
          <list-item>
            <p>Chili</p>
          </list-item>
          <list-item>
            <p>Chocolate</p>
          </list-item>
          <list-item>
            <p>Citric acid</p>
          </list-item>
          <list-item>
            <p>Citrus</p>
          </list-item>
          <list-item>
            <p>Cranberry juice</p>
          </list-item>
          <list-item>
            <p>Horseradish</p>
          </list-item>
          <list-item>
            <p>Hot peppers</p>
          </list-item>
          <list-item>
            <p>"Hot" sauces such as Tabasco</p>
          </list-item>
          <list-item>
            <p>Ketchup</p>
          </list-item>
          <list-item>
            <p>Pickles</p>
          </list-item>
          <list-item>
            <p>Pizza</p>
          </list-item>
          <list-item>
            <p>MSG</p>
          </list-item>
          <list-item>
            <p>Sauerkraut</p>
          </list-item>
          <list-item>
            <p>Spices</p>
          </list-item>
          <list-item>
            <p>Sweeteners (particularly artificial sweeteners such as saccharin)</p>
          </list-item>
          <list-item>
            <p>Tea</p>
          </list-item>
          <list-item>
            <p>Tomato juice</p>
          </list-item>
          <list-item>
            <p>Tomato sauce</p>
          </list-item>
          <list-item>
            <p>Tomatoes</p>
          </list-item>
          <list-item>
            <p>Vinegar</p>
          </list-item>
          <list-item>
            <p>Worcester sauce</p>
          </list-item>
        </list>
        <p>Myofascial release, physiotherapy with relaxation exercises, and pelvic floor trigger point manual therapy provided by a skilled practitioner have shown significant symptom relief in 70% of patients.<xref ref-type="bibr" rid="article-132252.r76">[77]</xref>&#x000a0;Standard pelvic floor strengthening treatments, such as Kegel exercises, may cause IC/BPS symptoms to worsen and are not recommended.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r77">[78]</xref>&#x000a0;</p>
        <p>Specific behaviors and activities that can help mitigate symptoms include the following:&#x000a0;<xref ref-type="bibr" rid="article-132252.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Avoidance of known dietary irritants (see list above)</p>
          </list-item>
          <list-item>
            <p>Bladder training with urge suppression</p>
          </list-item>
          <list-item>
            <p>Cognitive-behavioral therapy</p>
          </list-item>
          <list-item>
            <p>Dietary aids for bladder discomfort (calcium glycerophosphates, nutraceuticals, phenazopyridine)</p>
          </list-item>
          <list-item>
            <p>Increasing fluid intake to minimize urinary concentration</p>
          </list-item>
          <list-item>
            <p>Manual physical therapy for pelvic floor tenderness to relieve tender muscle points, contracture lengthening, and/or scars</p>
          </list-item>
          <list-item>
            <p>Meditation and imagery techniques for pain management</p>
          </list-item>
          <list-item>
            <p>Neuromodulation (can help urinary frequency/urgency but is relatively ineffective for pain control)</p>
          </list-item>
          <list-item>
            <p>Pelvic floor muscle relaxation training</p>
          </list-item>
          <list-item>
            <p>Stress management and reduction techniques</p>
          </list-item>
          <list-item>
            <p>Support groups</p>
          </list-item>
          <list-item>
            <p>Transcutaneous electrical nerve stimulation (TENS)</p>
          </list-item>
          <list-item>
            <p>Use of elimination diets to help determine which additional specific foods should be avoided</p>
          </list-item>
          <list-item>
            <p>Use of heat or cold to bladder and/or perineum for symptomatic relief</p>
          </list-item>
          <list-item>
            <p>Avoidance of behaviors and activities that are known to exacerbate bladder irritability, such as:
<list list-type="bullet"><list-item><p>Pelvic floor muscle strengthening exercises (Kegels)</p></list-item><list-item><p>Prolonged or untreated constipation</p></list-item><list-item><p>Sexual intercourse</p></list-item><list-item><p>Tight clothing</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pain Management</bold>
</p>
        <p>Most patients do not respond to a single agent, and a complex multidisciplinary option with expert guidance under a pain specialist or clinic should be sought. Treatment should be introduced slowly, with the lowest possible dose and&#x000a0;most minimal number of drugs used as possible, in line with the WHO pain ladder. Non-opioid treatments are much preferred over opioid therapy.<xref ref-type="bibr" rid="article-132252.r78">[79]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Acetaminophen</p>
          </list-item>
          <list-item>
            <p>Amitriptyline</p>
          </list-item>
          <list-item>
            <p>Gabapentin</p>
          </list-item>
          <list-item>
            <p>Hot sitz baths</p>
          </list-item>
          <list-item>
            <p>Intravesical "cocktail" therapy</p>
          </list-item>
          <list-item>
            <p>Meditation and imagery</p>
          </list-item>
          <list-item>
            <p>NSAIDs (ibuprofen, naproxen)</p>
          </list-item>
          <list-item>
            <p>Opioids</p>
          </list-item>
          <list-item>
            <p>Pregabalin</p>
          </list-item>
          <list-item>
            <p>Stress reduction</p>
          </list-item>
          <list-item>
            <p>Transcutaneous electrical nerve stimulation (TENS)</p>
          </list-item>
          <list-item>
            <p>Trigger point manual therapy</p>
          </list-item>
        </list>
        <p>
<bold>Pharmacological Therapy</bold>
</p>
        <p>Oral therapies have been used with moderate success for IC/BPS. Oral overactive bladder (OAB) medications, such as oxybutynin, have limited efficacy in controlling the urinary symptoms from IC/BPS, except possibly for some decrease in urinary frequency. Overactive bladder patients who fail to improve on OAB medications should be evaluated for possible IC/BPS.</p>
        <p>The most effective oral agents for treating IC/BPS are amitriptyline, cyclosporine A, and pentosan polysulfate.<xref ref-type="bibr" rid="article-132252.r79">[80]</xref><xref ref-type="bibr" rid="article-132252.r80">[81]</xref></p>
        <p><bold>Amitriptyline</bold> is a tricyclic antidepressant that has shown activity in reducing chronic pelvic pain, including discomfort from IC/BPS.<xref ref-type="bibr" rid="article-132252.r81">[82]</xref>&#x000a0;Adverse effects (drowsiness, nausea, lethargy, sedation) limit usefulness.<xref ref-type="bibr" rid="article-132252.r82">[83]</xref><xref ref-type="bibr" rid="article-132252.r83">[84]</xref><xref ref-type="bibr" rid="article-132252.r84">[85]</xref>&#x000a0;Low-dose (10 mg) amitriptyline combined with intravesical instillation therapy&#x000a0;is very effective, especially in improving the emotional status of patients with IC/BPS.<xref ref-type="bibr" rid="article-132252.r85">[86]</xref>&#x000a0;Standard dosing starts at 10 mg daily and gradually increases to a maximum of 100 mg as tolerated.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r82">[83]</xref></p>
        <p><bold>Cimetidine</bold> is an H2 blocker normally used for reducing gastric acid secretion, but it has also shown activity in reducing pain, frequency, and nocturia in approximately 60% to 70% of IC/BPS patients.<xref ref-type="bibr" rid="article-132252.r86">[87]</xref><xref ref-type="bibr" rid="article-132252.r87">[88]</xref><xref ref-type="bibr" rid="article-132252.r88">[89]</xref><xref ref-type="bibr" rid="article-132252.r89">[90]</xref>&#x000a0;The mechanism for this is unclear and occurs regardless of the presence or absence of increased mast cells in the bladder tissue.&#x000a0;No significant&#x000a0;adverse effects are reported with its use, and it is very cost-effective as it is not only generic but available without a prescription.<xref ref-type="bibr" rid="article-132252.r86">[87]</xref><xref ref-type="bibr" rid="article-132252.r87">[88]</xref></p>
        <p><bold>Cyclosporine A</bold>, an immunosuppressive drug that blocks cell-mediated immune reactions,&#x000a0;has shown superior efficacy compared to pentosan polysulfate, particularly in patients with Hunner ulcers who do not respond to triamcinolone injections or electrofulguration.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r71">[72]</xref><xref ref-type="bibr" rid="article-132252.r90">[91]</xref><xref ref-type="bibr" rid="article-132252.r91">[92]</xref>&#x000a0;A response rate of 84% has been reported in IC/BPS patients with Hunner ulcers treated with cyclosporine A.<xref ref-type="bibr" rid="article-132252.r80">[81]</xref>&#x000a0;It has also been suggested that it be considered for use in otherwise intractable cases.<xref ref-type="bibr" rid="article-132252.r90">[91]</xref></p>
        <p>While cyclosporine A has shown good efficacy in controlling pelvic and bladder symptoms, it has&#x000a0;only been used in relatively small numbers of IC/BPS patients. There are serious potential complications with regard to increased blood pressure, neurotoxicity, higher incidence of malignancies, greater infection risk due to immunosuppression, and decreased renal function.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r92">[93]</xref>&#x000a0;It also has a relatively short duration of action.&#x000a0;For these reasons, it is suggested to be used only by those familiar with this therapy and in patients with Hunner ulcers who fail other treatments.</p>
        <p>Currently, cyclosporine A is the only immunosuppressive agent recommended by the AUA for clinical use. After a full and frank review of the risks and potential benefits, a mutual decision between the doctor and patient is needed. The patient&#x000a0;must be fully aware of systemic immunosuppression risks, such as increased vulnerability to infection and the more rapid development of malignancies.&#x000a0;</p>
        <p>Experimentally, low-dose (1.5 mg/kg or less) cyclosporine A daily therapy has shown efficacy in providing long-term symptom relief when used immediately after Hunner ulcer fulguration. The lower dose limits&#x000a0;adverse effects. Further studies are necessary until this approach's long-term safety and efficacy have been conclusively determined.<xref ref-type="bibr" rid="article-132252.r93">[94]</xref></p>
        <p><bold>Gabapentin</bold> has shown some activity in reducing pain and other symptoms of IC/BPS.<xref ref-type="bibr" rid="article-132252.r94">[95]</xref><xref ref-type="bibr" rid="article-132252.r95">[96]</xref><xref ref-type="bibr" rid="article-132252.r96">[97]</xref><xref ref-type="bibr" rid="article-132252.r97">[98]</xref>&#x000a0;Gabapentin was originally approved as an antiepileptic but has since found a role in managing various types of neuropathic pain. Dosage starts at 300 mg TID, which is then slowly titrated up to a maximum of 1,200 mg TID.<xref ref-type="bibr" rid="article-132252.r98">[99]</xref></p>
        <p><bold>Hydroxyzine</bold> is an antihistamine and mast cell stabilizer that has shown effectiveness in providing significant symptom relief in some IC/BPS patients.&#x000a0;Those IC/BPS patients with allergies may most likely benefit from this treatment.<xref ref-type="bibr" rid="article-132252.r99">[100]</xref>&#x000a0; Hydroxyzine prevents the degranulation of mast cells, reducing the release of toxic agents that would otherwise cause inflammation and IC/BPS symptoms in some patients.&#x000a0;The degranulation of mast cells causes the release of neuroactive and vasoactive agents and is believed to be responsible for the symptoms of IC/BPS, at least in some patients.<xref ref-type="bibr" rid="article-132252.r100">[101]</xref>&#x000a0;Adverse effects tend to be minor and include mild sedation and weakness. The dosage is usually 50 mg to 100 mg QID.</p>
        <p><bold>Overactive bladder (OAB) medications</bold>&#x000a0;(oxybutynin, mirabegron, etc) are usually insufficient when used alone in managing the urinary symptoms of IC/BPS. These medications may be beneficial in reducing frequency and urgency, but they generally do not help with pain where a multimodal approach is typically needed.<xref ref-type="bibr" rid="article-132252.r101">[102]</xref><xref ref-type="bibr" rid="article-132252.r102">[103]</xref>&#x000a0;Patients with significant OAB symptoms who fail standard treatment should be considered for possible IC/BPS.</p>
        <p><bold>Pentosan polysulfate</bold> is the only FDA-approved oral medication approved for IC/BPS.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;It acts by restoring a protective layer over the bladder mucosal lining. Studies on its efficacy are conflicting; some show a benefit while others do not.<xref ref-type="bibr" rid="article-132252.r99">[100]</xref><xref ref-type="bibr" rid="article-132252.r103">[104]</xref><xref ref-type="bibr" rid="article-132252.r104">[105]</xref><xref ref-type="bibr" rid="article-132252.r105">[106]</xref><xref ref-type="bibr" rid="article-132252.r106">[107]</xref><xref ref-type="bibr" rid="article-132252.r107">[108]</xref>&#x000a0;Maximum symptomatic relief may take up to 5 or&#x000a0;6 months or longer.<xref ref-type="bibr" rid="article-132252.r108">[109]</xref><xref ref-type="bibr" rid="article-132252.r109">[110]</xref></p>
        <p>A worrisome retinal pigmentary maculopathy has now been clearly associated with the long-term, cumulative use of pentosan polysulfate.<xref ref-type="bibr" rid="article-132252.r110">[111]</xref><xref ref-type="bibr" rid="article-132252.r111">[112]</xref><xref ref-type="bibr" rid="article-132252.r112">[113]</xref><xref ref-type="bibr" rid="article-132252.r113">[114]</xref><xref ref-type="bibr" rid="article-132252.r114">[115]</xref>&#x000a0;Symptoms include blurred vision, delayed adjustment to low-light situations, and difficulty reading. Patients should be warned about these effects, that they are related to the total cumulative amount of therapy, and that the visual damage does not appear to be reversible.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r109">[110]</xref><xref ref-type="bibr" rid="article-132252.r115">[116]</xref>&#x000a0;</p>
        <p>For those who choose to use the medication, a retinal examination prior to initiating treatment is recommended,&#x000a0;and a recheck at 6 months and periodically thereafter.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r109">[110]</xref>&#x000a0;Recent evidence suggests that the retinal macular damage may continue even after cessation of the pentosan polysulfate, and the damage is irreversible.<xref ref-type="bibr" rid="article-132252.r115">[116]</xref>&#x000a0;This new data is very worrisome and makes pentosan polysulfate a far less attractive therapy as an oral agent.<xref ref-type="bibr" rid="article-132252.r116">[117]</xref>&#x000a0;For these reasons, pentosan polysulfate is now used infrequently for IC/BPS.</p>
        <p><bold>Sacral neuromodulation</bold> has been shown in most studies to be a reasonably effective treatment for controlling intractable bladder overactivity and chronic pelvic pain in some IC/BPS patients.<xref ref-type="bibr" rid="article-132252.r117">[118]</xref><xref ref-type="bibr" rid="article-132252.r118">[119]</xref>&#x000a0;It is FDA-approved only for severe bladder overactivity and frequency, for which it seems more effective than its effect on pain control in IC/BPS.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r119">[120]</xref>&#x000a0;Tibial nerve stimulation has also shown a benefit in treating IC/BPS.<xref ref-type="bibr" rid="article-132252.r120">[121]</xref><xref ref-type="bibr" rid="article-132252.r121">[122]</xref>&#x000a0;A clinical&#x000a0;trial of sacral neuromodulation or tibial nerve stimulation can be reasonably considered in selected IC/BPS patients who have failed other treatment modalities.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r117">[118]</xref><xref ref-type="bibr" rid="article-132252.r119">[120]</xref><xref ref-type="bibr" rid="article-132252.r122">[123]</xref></p>
        <p>
<bold>Intravesical Instillations</bold>
</p>
        <p>Various medications are effective when used as intravesical instillation therapy in IC/BPS when oral pharmaceuticals and dietary measures alone are insufficient.<xref ref-type="bibr" rid="article-132252.r123">[124]</xref> No optimal or ideal cocktail has yet been agreed upon. The most commonly used medications include the following:</p>
        <p><bold>Dimethylsulfoxide (DMSO)</bold> is an effective agent for symptom control when used as an intravesical instillation in patients with IC/BPS.<xref ref-type="bibr" rid="article-132252.r124">[125]</xref><xref ref-type="bibr" rid="article-132252.r125">[126]</xref><xref ref-type="bibr" rid="article-132252.r126">[127]</xref><xref ref-type="bibr" rid="article-132252.r127">[128]</xref>&#x000a0;It acts as an anti-inflammatory and a topical anesthetic, rapidly absorbed into the bladder mucosa and detrusor. It is a carrier, meaning it greatly enhances the absorption of other agents with which it may be combined. This should be considered when putting together a cocktail "recipe" to avoid potential toxicity. It is often mixed with bupivacaine or lidocaine, heparin, sodium bicarbonate, and hydrocortisone or triamcinolone.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;</p>
        <p>DMSO by itself is odorless, but when used in patients, it causes an extremely strong garlic odor that can last up to 72 hours following intravesical administration. This makes it unacceptable for some patients.</p>
        <p>The results were similar when instillations of DMSO alone were compared to applications of a standard intravesical cocktail of bupivacaine, heparin, and triamcinolone.<xref ref-type="bibr" rid="article-132252.r128">[129]</xref>&#x000a0;However, bladder instillations of&#x000a0;DMSO plus triamcinolone were found to be significantly (50%) superior in symptom relief compared to the same standard intravesical cocktail of bupivacaine, heparin, and triamcinolone in newly diagnosed women with IC/BPS.<xref ref-type="bibr" rid="article-132252.r125">[126]</xref>&#x000a0;There is also evidence that DMSO may be more effective in patients with Hunner ulcers.<xref ref-type="bibr" rid="article-132252.r129">[130]</xref></p>
        <p>DMSO becomes painful if held in the bladder longer than about 20 minutes.&#x000a0;The typical dose is 50 mL of a 50% DMSO solution.&#x000a0;Intravesical instillation of DMSO is FDA-approved and recommended by the AUA guidelines.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref></p>
        <p><bold>Some experts have added gentamicin, an aminoglycoside antibiotic</bold>, into&#x000a0;intravesical cocktail formulas in certain situations. Antibiotics are not routinely recommended for intravesical IC/BPS therapy, but adding gentamicin may be a reasonable precaution for patients who have had recent infections or where there is evidence of bacteriuria or pyuria. Patients with an active infection should not have IC/BPS intravesical instillations until the infection is cleared. There is no evidence that gentamicin alone has any significant efficacy in treating IC/BPS directly. The typical dose is 80 mg.</p>
        <p><bold>Heparin</bold> acts as a synthetic GAG layer to help protect the bladder mucosa from urinary irritants when used for intravesical therapy in IC/BPS patients.&#x000a0;Initial studies with heparin used only 10,000 IU&#x000a0;3 times a week for&#x000a0;3 months and reported significant improvement in 56% of patients.<xref ref-type="bibr" rid="article-132252.r130">[131]</xref>&#x000a0;Heparin&#x000a0;is more effective than lidocaine alone for relieving IC/BPS symptoms.<xref ref-type="bibr" rid="article-132252.r131">[132]</xref><xref ref-type="bibr" rid="article-132252.r132">[133]</xref>&#x000a0;Most intravesical instillation cocktails include heparin, which the AUA guidelines recommend.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r133">[134]</xref></p>
        <p>The typical dose is 10,000 IU to 20,000 IU, but dosages up to 50,000 IU have been used as the optimal dose has not been determined.<xref ref-type="bibr" rid="article-132252.r133">[134]</xref>&#x000a0;</p>
        <p><bold>Hyaluronic acid</bold>&#x000a0;alone or with chondroitin sulfate has shown some efficacy in treating patients with IC/BPS.<xref ref-type="bibr" rid="article-132252.r134">[135]</xref><xref ref-type="bibr" rid="article-132252.r135">[136]</xref><xref ref-type="bibr" rid="article-132252.r136">[137]</xref><xref ref-type="bibr" rid="article-132252.r137">[138]</xref>&#x000a0;Both of these chemicals are decreased in chronically inflamed bladders. Hyaluronic acid is a mucopolysaccharide non-sulfated component of the normal bladder&#x000a0;GAG layer. There is no standard dosing schedule or good data on this medication, but the most recent review used 40 mg starting at several treatments a week and then extending the time interval based on the response. The Spanish Association of Urology conducted the review through the Functional, Female, and Urodynamic Urology Group, which found that dosage and schedule to be safe and effective.<xref ref-type="bibr" rid="article-132252.r134">[135]</xref>&#x000a0;A study from Taiwan used a schedule of&#x000a0;4 weekly intravesical treatments followed by monthly therapy for&#x000a0;5 months. They reported improved urinary symptoms in 73% of patients.<xref ref-type="bibr" rid="article-132252.r138">[139]</xref>&#x000a0;Another study of intravesical hyaluronic acid found it to be more effective for relieving bladder pain than alleviating urinary storage symptoms.<xref ref-type="bibr" rid="article-132252.r139">[140]</xref></p>
        <p><bold>Lidocaine</bold> is a local anesthetic that has demonstrated usefulness in reducing short-term (&#x0003c;2 weeks) bladder pain and symptoms when used for intravesical therapy. Lidocaine reduces histamine release from mast cells, exerts an anti-inflammatory effect on eosinophils, decreases leukocyte adherence, and is bactericidal.<xref ref-type="bibr" rid="article-132252.r140">[141]</xref>&#x000a0;Alkalinization with sodium bicarbonate improves bladder tissue penetration, potentially leading to toxicity.<xref ref-type="bibr" rid="article-132252.r131">[132]</xref><xref ref-type="bibr" rid="article-132252.r132">[133]</xref>&#x000a0;</p>
        <p>The AUA guidelines recommend lidocaine as an effective agent for IC/BPS when used in an intravesical cocktail.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref> A typical intravesical dose&#x000a0;is 25 mL to 50 mL of a 2% lidocaine solution or viscous gel.&#x000a0;Bupivacaine (a longer-acting lidocaine analog) 0.5% is usually dosed at 10 mL to 20 mL for intravesical use.&#x000a0;Sodium bicarbonate (alkalinizer) is typically given as an 8.4% solution in 5 mL to 50 mL volumes.</p>
        <p><bold>Misoprostol</bold> is a prostaglandin E1 analog used orally to help prevent gastric ulcers from heavy NSAID use by interfering with nuclear factor kappa B (NF-kappa B) signaling activity. This interference affects cytokine production, DNA transcription, immune response, and cell survival.<xref ref-type="bibr" rid="article-132252.r141">[142]</xref> This same pathway is activated in patients with IC/BPS bladders.<xref ref-type="bibr" rid="article-132252.r142">[143]</xref> Additionally, misoprostol acts&#x000a0;synergistically when used with cyclosporine and enhances&#x000a0;GAG synthesis.<xref ref-type="bibr" rid="article-132252.r143">[144]</xref>&#x000a0;</p>
        <p>It was&#x000a0;theorized by Dr. Ray Rackley at the Cleveland Clinic that misoprostol might be helpful when used intravesically for IC/BPS. It is typically added to intravesical cocktails when they are ineffective before advancing to more invasive therapeutic options.<xref ref-type="bibr" rid="article-132252.r144">[145]</xref>&#x000a0;There are isolated anecdotal reports and small studies of&#x000a0;misoprostol helping IC/BPS patients both as an oral agent (200 mcg TID) and as a supplement to an intravesical cocktail (200 mcg to 400 mcg).<xref ref-type="bibr" rid="article-132252.r145">[146]</xref><xref ref-type="bibr" rid="article-132252.r146">[147]</xref></p>
        <p><bold>Triamcinolone</bold> is a frequent ingredient in IC/BPS intravesical cocktails as an anti-inflammatory agent, but its effectiveness is unclear. A randomized trial of&#x000a0;2 identical cocktails, except for adding triamcinolone to one, demonstrated no detectable difference in efficacy as both groups improved similarly.<xref ref-type="bibr" rid="article-132252.r147">[148]</xref>&#x000a0;The studied cocktails did not include DMSO, which has proven efficacy when combined with triamcinolone.<xref ref-type="bibr" rid="article-132252.r125">[126]</xref>&#x000a0;Taken together, this suggests some efficacy, particularly when combined with DMSO. Triamcinolone is a frequent ingredient in many intravesical cocktails used for IC/BPS. The typical dosage used is 40 mg or 80 mg.</p>
        <p>Intravesical triamcinolone injections for patients with Hunner ulcers have clearly shown effectiveness in IC/BPS and are recommended by the AUA guidelines when these pathognomonic lesions are found.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r148">[149]</xref></p>
        <p>
<bold>Electromotive Drug Administration (EMDA)</bold>
</p>
        <p>EMDA is a method of improving bladder tissue penetration of intravesical drug instillations. A low-voltage gradient is created using electrical probes in the bladder and abdomen, creating a voltage differential that enhances drug delivery and improves tissue penetration.&#x000a0;</p>
        <p>A small randomized prospective trial demonstrated improved short-term efficacy.<xref ref-type="bibr" rid="article-132252.r149">[150]</xref>&#x000a0;The main issue with the study is the small sample size (n=31). Additional extensive, randomized, long-term studies are needed to compare EMDA to current passive diffusion to determine its ultimate efficacy, cost-effectiveness, safety, and utility.<xref ref-type="bibr" rid="article-132252.r150">[151]</xref></p>
        <p>
<bold>Botulinum Toxin Type A Detrusor Injections</bold>
</p>
        <p>Botulinum toxin A has been widely used for neurogenic detrusor overactivity, overactive bladder, and detrusor-sphincter dyssynergia to help control urinary symptoms in patients with IC/BPS. Botulinum toxin A can inhibit the release of sensory nerve terminal vesicles, which can help reduce inflammation in addition to its effect on bladder motor activity.<xref ref-type="bibr" rid="article-132252.r31">[31]</xref> It is effective for individuals with IC/BPS when used alone or with hydrodistension and can also reduce pain.<xref ref-type="bibr" rid="article-132252.r151">[152]</xref><xref ref-type="bibr" rid="article-132252.r152">[153]</xref><xref ref-type="bibr" rid="article-132252.r153">[154]</xref><xref ref-type="bibr" rid="article-132252.r154">[155]</xref><xref ref-type="bibr" rid="article-132252.r155">[156]</xref><xref ref-type="bibr" rid="article-132252.r156">[157]</xref><xref ref-type="bibr" rid="article-132252.r157">[158]</xref>&#x000a0;The overall success rate with botulinum toxin type A bladder injections is reported to be over 60%.<xref ref-type="bibr" rid="article-132252.r158">[159]</xref></p>
        <p>Retreatments with botulinum toxin A remained effective when the initial therapeutic benefit faded.<xref ref-type="bibr" rid="article-132252.r159">[160]</xref>&#x000a0;</p>
        <p>The European Association of Urology recommends hydrodistension followed by botulinum toxin detrusor injections for intravesical instillation therapy failures.</p>
        <p>Postvoid residual volumes tend to increase, and even successfully treated patients may notice some dysuria or difficulty in voiding. The therapy will eventually wear off after some months, so retreatments are to be expected. There is also a risk of urinary retention after botulinum toxin A bladder injections, which is why it is most useful in patients who can do intermittent self-catheterization if necessary.</p>
        <p>A 2020 meta-analysis reviewed treatment efficacy in IC/BPS symptom control from all available treatments as reported in 81 randomized, controlled trials. The review focused on antidepressants, neuromuscular blockade (botulinum toxin A), and pentosan polysulfate therapies. Intravesical instillations were not included due to inadequate numbers meeting reporting and statistical criteria. The study found improved outcomes only from botulinum toxin A therapy.<xref ref-type="bibr" rid="article-132252.r160">[161]</xref></p>
        <p>Intravesical detrusor injections of botulinum toxin A are recommended in the AUA guidelines for use when other oral and intravesical options have failed, but only for patients willing and able to perform intermittent self-catheterization after treatment if necessary.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref>&#x000a0;Alternate delivery systems that do not require detrusor injections are being studied.</p>
        <p>
<bold>Cystoscopy Guided Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cystoscopy is&#x000a0;performed to rule out other diagnoses and to look for Hunner ulcers.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If Hunner lesions are present, they can be treated using direct fulguration with electrocautery or laser and/or injection of triamcinolone.&#x000a0;
<list list-type="bullet"><list-item><p>Oral cyclosporine A is recommended if this fails.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If no Hunner ulcers are found at cystoscopy, short-duration, low-pressure hydrodistension under anesthesia can be performed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Low-pressure, short-duration hydrodistension under anesthesia offers substantial pain relief to some patients but risks a temporary symptom flair.<xref ref-type="bibr" rid="article-132252.r161">[162]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>High-pressure hydrodistension under anesthesia is not recommended due to inconsistent symptom improvement and an increased risk of sepsis and bladder rupture.<xref ref-type="bibr" rid="article-132252.r162">[163]</xref></p>
          </list-item>
        </list>
        <p><bold>Neuromodulation</bold>&#x000a0;</p>
        <p>Neuromodulation&#x000a0;has been shown in most studies to be a reasonably effective treatment for controlling intractable bladder overactivity and chronic pelvic pain in some patients who have not achieved adequate symptom control with other modalities.<xref ref-type="bibr" rid="article-132252.r118">[119]</xref>&#x000a0;Neuromodulation therapy is FDA-approved only for intractable bladder overactivity and frequency, which seems more effective than its effect on pain control in IC/BPS.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r117">[118]</xref><xref ref-type="bibr" rid="article-132252.r119">[120]</xref><xref ref-type="bibr" rid="article-132252.r163">[164]</xref><xref ref-type="bibr" rid="article-132252.r164">[165]</xref><xref ref-type="bibr" rid="article-132252.r165">[166]</xref></p>
        <p>Sacral neuromodulation&#x000a0;has been shown in most studies to be a reasonably effective treatment for controlling intractable bladder overactivity and chronic pelvic pain in some IC/BPS patients.<xref ref-type="bibr" rid="article-132252.r117">[118]</xref><xref ref-type="bibr" rid="article-132252.r118">[119]</xref>&#x000a0;It is FDA-approved only for severe bladder overactivity and frequency, for which it seems more effective than its effect on pain control in IC/BPS.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r119">[120]</xref>&#x000a0;</p>
        <p>The treatment is relatively invasive, expensive, frequently requires reprogramming, may need a reoperation, and lacks long-term data on efficacy. Complications include infection or pain at the implantation site, lead migration, and loss of efficacy over time.&#x000a0;Tibial nerve stimulation has also been beneficial in treating patients with IC/BPS.<xref ref-type="bibr" rid="article-132252.r120">[121]</xref><xref ref-type="bibr" rid="article-132252.r121">[122]</xref>&#x000a0;</p>
        <p>A clinical&#x000a0;trial of sacral neuromodulation or tibial nerve stimulation can be reasonably considered in selected IC/BPS patients who have failed other treatments.<xref ref-type="bibr" rid="article-132252.r1">[1]</xref><xref ref-type="bibr" rid="article-132252.r117">[118]</xref><xref ref-type="bibr" rid="article-132252.r119">[120]</xref><xref ref-type="bibr" rid="article-132252.r120">[121]</xref><xref ref-type="bibr" rid="article-132252.r121">[122]</xref><xref ref-type="bibr" rid="article-132252.r122">[123]</xref></p>
        <p><bold>Treatments Specifically Not Recommended</bold>&#x000a0;</p>
        <p>Treatments that are specifically not recommended by multiple sources (the American Urological Association, the National Institute for Clinical Excellence, and the European Association of Urology) include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravesical BCG</p>
          </list-item>
          <list-item>
            <p>Intravesical clorpactin (oxychlorosene)</p>
          </list-item>
          <list-item>
            <p>Long-term oral antibiotics</p>
          </list-item>
          <list-item>
            <p>Prolonged high-pressure bladder hydrodistention&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prolonged oral steroids&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Surgical Treatment</bold>
</p>
        <p>Surgery&#x000a0;has recently seen a fall in popularity, especially after the introduction of intra-detrusor injections of Botulinum toxin A. However, surgery remains the last resort option for patients with intractable disease as a final resolution of symptoms. About 75% of patients can expect pain relief with open surgery. A urethrectomy is usually not necessary and adds considerable time and morbidity to the procedure.<xref ref-type="bibr" rid="article-132252.r166">[167]</xref>&#x000a0;</p>
        <p>A supra-trigonal bladder resection with augmentation ileocystoplasty has been suggested as it appears to be a successful surgical therapy for most of these patients and avoids the need for a urostomy.<xref ref-type="bibr" rid="article-132252.r166">[167]</xref><xref ref-type="bibr" rid="article-132252.r167">[168]</xref><xref ref-type="bibr" rid="article-132252.r168">[169]</xref><xref ref-type="bibr" rid="article-132252.r169">[170]</xref>&#x000a0;Good results have been reported with over 14 years of follow-up using this procedure.<xref ref-type="bibr" rid="article-132252.r169">[170]</xref><xref ref-type="bibr" rid="article-132252.r170">[171]</xref>&#x000a0;Concern about inadequate symptom control, if the trigone is not removed appears unfounded.<xref ref-type="bibr" rid="article-132252.r169">[170]</xref><xref ref-type="bibr" rid="article-132252.r170">[171]</xref>&#x000a0;A combined robot-assisted laparoscopic and mini-laparotomy approach for this procedure has been described and used successfully.<xref ref-type="bibr" rid="article-132252.r166">[167]</xref><xref ref-type="bibr" rid="article-132252.r169">[170]</xref></p>
        <p>A summary of possible last-resort surgical options includes the following:&#x000a0;<xref ref-type="bibr" rid="article-132252.r171">[172]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Cystoplasty only</p>
          </list-item>
          <list-item>
            <p>Cystoplasty with supra-trigonal resection</p>
          </list-item>
          <list-item>
            <p>Cystoplasty with sub-trigonal resection</p>
          </list-item>
          <list-item>
            <p>Urinary diversion, with or without cystectomy, usually with an ileal conduit</p>
          </list-item>
        </list>
        <p>
<bold>Investigational Therapies</bold>
</p>
        <p>Monoclonal antibody therapy has shown some promise, but additional research needs to be done to find the ideal antibody mix.<xref ref-type="bibr" rid="article-132252.r172">[173]</xref></p>
        <p>Certolizumab pegol is an investigational pharmacologic therapy under development for treating IC/BPS.<xref ref-type="bibr" rid="article-132252.r81">[82]</xref></p>
        <p>Chondroitin sulfate (2% solution) is approved for intravesical use in Europe and Canada. Chondroitin appears to repair, restore, or replace the mucosal&#x000a0;GAG layer and is often used with hyaluronic acid.<xref ref-type="bibr" rid="article-132252.r173">[174]</xref><xref ref-type="bibr" rid="article-132252.r174">[175]</xref><xref ref-type="bibr" rid="article-132252.r175">[176]</xref><xref ref-type="bibr" rid="article-132252.r176">[177]</xref></p>
        <p>Hyperbaric oxygen therapy appears beneficial in treating IC/BPS patients, but it requires a special chamber, is not very cost-effective, and is quite time-consuming.<xref ref-type="bibr" rid="article-132252.r177">[178]</xref><xref ref-type="bibr" rid="article-132252.r178">[179]</xref>&#x000a0;There is limited data on long-term results.</p>
        <p>Intravesical liposomes have shown activity in reducing symptoms of IC/BPS.<xref ref-type="bibr" rid="article-132252.r179">[180]</xref><xref ref-type="bibr" rid="article-132252.r180">[181]</xref>&#x000a0;Liposomes can be used as biocompatible lipid-based drug carriers for intravesical therapy.&#x000a0;They tend to stick to the bladder walls, and their lipid-based walls reduce mucosal inflammation while promoting and facilitating drug penetration (such as Botulinum toxin type A) into bladder tissue.<xref ref-type="bibr" rid="article-132252.r180">[181]</xref>&#x000a0;While promising, only limited data is currently available, and long-term, randomized prospective trials are needed.</p>
        <p>Mesenchymal stem cells may be valuable in treating patients with IC/BPS as they have been shown to minimize bladder tissue injury and inflammation.&#x000a0;After migrating into the detrusor tissue, they differentiate into bladder cells, inhibit mast cell buildup, decrease cellular apoptosis, reduce inflammation, mitigate oxidative stress, diminish collagen deposition, and promote normal regenerative functions.&#x000a0;Mesenchymal stem cells also secrete exosomes and other factors that protect against tissue injury.<xref ref-type="bibr" rid="article-132252.r181">[182]</xref></p>
        <p>Platelet-rich plasma&#x000a0;is widely used to promote wound healing.<xref ref-type="bibr" rid="article-132252.r182">[183]</xref>&#x000a0;It contains abundant cytokines and growth factors that affect the inflammatory process to promote healing and reduce neuropathic pain.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref><xref ref-type="bibr" rid="article-132252.r183">[184]</xref><xref ref-type="bibr" rid="article-132252.r184">[185]</xref>&#x000a0;Direct platelet-rich plasma detrusor injections have been shown to increase urothelial cell growth, decrease inflammation, improve mucosal lining barrier function, repair ultrastructural damage, and relieve symptoms.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref><xref ref-type="bibr" rid="article-132252.r177">[178]</xref><xref ref-type="bibr" rid="article-132252.r185">[186]</xref><xref ref-type="bibr" rid="article-132252.r186">[187]</xref><xref ref-type="bibr" rid="article-132252.r187">[188]</xref><xref ref-type="bibr" rid="article-132252.r188">[189]</xref><xref ref-type="bibr" rid="article-132252.r189">[190]</xref></p>
        <p>Low-energy shock wave therapy has experimentally shown a benefit in reducing bladder pain, decreasing tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), and lowering nerve growth factor (NGF) in IC/BPS patients.<xref ref-type="bibr" rid="article-132252.r190">[191]</xref>&#x000a0;It suppresses bladder overactivity, reduces the inflammatory response, and increases urothelial permeability, making it potentially valuable for enhancing the penetration of therapeutic drug instillations of bladder tissue.<xref ref-type="bibr" rid="article-132252.r191">[192]</xref>&#x000a0;</p>
        <p>A preliminary study has shown that low-energy shock wave therapy can allow for bladder muscle absorption of intravesical instillation of botulinum toxin A with a corresponding improvement in IC/BPS symptoms.<xref ref-type="bibr" rid="article-132252.r191">[192]</xref>&#x000a0;The benefit of this approach is that it does not require invasive detrusor injections or anesthesia, appears to be safe and effective with no reported&#x000a0;adverse effects, and combines the benefits of&#x000a0;2 different therapeutic modalities. These results are very preliminary, and substantial study is needed before such treatments can be recommended for clinical use.</p>
        <p>The chronic inflammatory bladder changes and negative bacterial cultures associated with IC/BPS could be explained by a viral infection such as Epstein-Barr virus (EBV), found in up to 87.5% of patients.<xref ref-type="bibr" rid="article-132252.r192">[193]</xref>&#x000a0;This suggests the possible use of valacyclovir as an antiviral treatment in infected individuals.&#x000a0;Early unpublished data suggest this may be a promising treatment, particularly for patients unresponsive to other therapies who are shown to have EBV exposure.<xref ref-type="bibr" rid="article-132252.r13">[13]</xref>&#x000a0;</p>
        <p>
<bold>Treatment Summary</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Conservative treatment of IC/BPS involves dietary adjustments, pelvic floor relaxation therapies, myofascial release and trigger point therapy, and stress reduction.</p>
          </list-item>
          <list-item>
            <p>Initial oral pharmacotherapy includes amitriptyline, cimetidine, and hydroxyzine.</p>
          </list-item>
          <list-item>
            <p>Oral pentosan polysulfate may be effective in some patients but is associated with potentially significant and permanent retinal damage.</p>
          </list-item>
          <list-item>
            <p>OAB medications can help with urinary symptoms but are generally insufficient when used alone.</p>
          </list-item>
          <list-item>
            <p>Gabapentin may be useful for pain control.</p>
          </list-item>
          <list-item>
            <p>Cyclosporine A can be used in patients with Hunner ulcers who have failed fulguration and/or triamcinolone injection therapy.</p>
          </list-item>
          <list-item>
            <p>Intravesical instillations are very effective non-surgical therapies. Recommended drug cocktail options include DMSO, lidocaine (or bupivacaine) with sodium bicarbonate, and heparin.</p>
          </list-item>
          <list-item>
            <p>Additional intravesical drugs include chondroitin sulfate, hyaluronic acid, misoprostol, and triamcinolone.</p>
          </list-item>
          <list-item>
            <p>Cystoscopy with low-pressure, short-duration hydrodistension and possible direct Hunner ulcer therapy should be considered for patients who continue to have symptoms.</p>
          </list-item>
          <list-item>
            <p>Patients who do not respond adequately to the above treatments may be candidates for the following:
<list list-type="bullet"><list-item><p>Botulinum toxin A detrusor injections</p></list-item><list-item><p>Cyclosporine A</p></list-item><list-item><p>Neuromodulation</p></list-item><list-item><p>Misoprostol (oral or intravesical)</p></list-item><list-item><p>Tibial nerve stimulation</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Definitive surgical therapy is reserved for patients who continue to have significant symptoms that have not been adequately controlled with any of the listed alternative treatments.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132252.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The possible&#x000a0;list of differential diagnoses is extensive, and this list is not exhaustive, but the causes can be broken down into categories as follows:&#x000a0;<xref ref-type="bibr" rid="article-132252.r193">[194]</xref></p>
        <p>
<bold>Infections</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sexually transmitted infections such as chlamydia and gonorrhoea</p>
          </list-item>
          <list-item>
            <p>Tuberculous infections of the bladder</p>
          </list-item>
          <list-item>
            <p>Urinary tract infections</p>
          </list-item>
        </list>
        <p>
<bold>Urological and Urogynecological Conditions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bladder stones</p>
          </list-item>
          <list-item>
            <p>Chronic urethral syndrome</p>
          </list-item>
          <list-item>
            <p>Distal ureteral calculi</p>
          </list-item>
          <list-item>
            <p>Pelvic organ prolapse</p>
          </list-item>
          <list-item>
            <p>Prior pelvic surgery, especially involving mesh</p>
          </list-item>
          <list-item>
            <p>Prostate pathology, including but not limited to benign prostatic hyperplasia, prostate cancer, and chronic prostatitis</p>
          </list-item>
          <list-item>
            <p>Neoplasms of the urinary bladder</p>
          </list-item>
          <list-item>
            <p>Neurogenic bladder&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Overactive bladder</p>
          </list-item>
          <list-item>
            <p>Stress incontinence</p>
          </list-item>
          <list-item>
            <p>Urge incontinence/detrusor instability</p>
          </list-item>
        </list>
        <p>
<bold>Gynecological Conditions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Endometriosis</p>
          </list-item>
          <list-item>
            <p>Pelvic inflammatory disease</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Vulvodynia</p>
          </list-item>
        </list>
        <p>
<bold>Neurological</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cauda equina/cord compression</p>
          </list-item>
          <list-item>
            <p>Demyelinating diseases</p>
          </list-item>
          <list-item>
            <p>Diabetic neuropathy</p>
          </list-item>
          <list-item>
            <p>Pudendal neuralgia</p>
          </list-item>
          <list-item>
            <p>Stroke</p>
          </list-item>
        </list>
        <p>
<bold>Other Causes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Congenital bladder malformations</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Diverticular disease</p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease</p>
          </list-item>
          <list-item>
            <p>Radiation-induced effects</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Trauma</p>
          </list-item>
          <list-item>
            <p>Urinary diverticula</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132252.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The majority of patients suffer from chronic symptoms with periodic exacerbations and remissions of varying intervals, but there is a wide variation in prognosis, course, and resolution. Patterns of the disease have been observed and described. These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete resolution</p>
          </list-item>
          <list-item>
            <p>Relapsing-remitting</p>
          </list-item>
          <list-item>
            <p>Intermittent disease flares</p>
          </list-item>
          <list-item>
            <p>Chronic progression</p>
          </list-item>
        </list>
        <p>The patient may also experience spontaneous resolution and unexpected recurrences regardless of treatment.<xref ref-type="bibr" rid="article-132252.r194">[195]</xref></p>
        <p>IC/BPS appears to be an extremely stable condition, as urinary symptoms and discomfort tend to remain unchanged in severity for up to&#x000a0;9 years.<xref ref-type="bibr" rid="article-132252.r195">[196]</xref></p>
      </sec>
      <sec id="article-132252.s12" sec-type="Complications">
        <title>Complications</title>
        <p>If left untreated and without spontaneous resolution, the bladder may undergo&#x000a0;more fibrosis, further reducing the bladder volume and further compounding the symptoms experienced. The patient would experience psychological and social health deterioration through sleep disturbance, sexual dysfunction, anxiety, depression, and social embarrassment.</p>
        <p>Treatment complications depend on various factors, such as the pharmacological agent, cystoscopy, or surgical complications.&#x000a0;Proper counseling and consent before treatment are paramount.<xref ref-type="bibr" rid="article-132252.r196">[197]</xref>&#x000a0;Complications can be broadly categorized as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bleeding</p>
          </list-item>
          <list-item>
            <p>COVID-19&#x000a0;<xref ref-type="bibr" rid="article-132252.r197">[198]</xref></p>
          </list-item>
          <list-item>
            <p>Death (from procedure or anesthesia)</p>
          </list-item>
          <list-item>
            <p>Infection (introduced through intravesical routes or surgery)</p>
          </list-item>
          <list-item>
            <p>Perforation of the bladder during high-pressure hydrodistention</p>
          </list-item>
          <list-item>
            <p>Trauma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anesthetic complications are predominantly due to human factors and have an estimated mortality of 0.4 per 100,000 patients.<xref ref-type="bibr" rid="article-132252.r198">[199]</xref>&#x000a0;Anesthetic&#x000a0;complications include the following:&#x000a0;<xref ref-type="bibr" rid="article-132252.r199">[200]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>Anaphylaxis</p></list-item><list-item><p>Aspiration</p></list-item><list-item><p>Cardiovascular collapse</p></list-item><list-item><p>Medication errors</p></list-item><list-item><p>Nausea and vomiting</p></list-item><list-item><p>Respiratory depression&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>There is also a theoretical risk of urinary tract infections. The symptoms may change and worsen during this time, and tests for infection should always be checked in those circumstances. This is due to the damage and breach of the urothelium, which increases the probability of bacterial invasion, bladder damage, and symptoms. A short course of therapeutic antibiotics could be started in selected cases like these, but prolonged treatment is not recommended for therapy or prophylaxis.</p>
      </sec>
      <sec id="article-132252.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Once the diagnosis is made, the patient should be counseled on what that means, why they experience the symptoms, and that the etiology is not well-understood at present.</p>
        <p>The patient should be directed and encouraged to engage with self-help and local support groups, such as those offered by the<italic toggle="yes"> Interstitial Cystitis Association</italic>&#x000a0;(https://www.ichelp.org/)&#x000a0;in the United States and&#x000a0;<italic toggle="yes">Bladder Health UK</italic>&#x000a0;or <italic toggle="yes">PainUK</italic> in the United Kingdom.&#x000a0;Some patients who have used self-help resources found it a very effective treatment option.<xref ref-type="bibr" rid="article-132252.r200">[201]</xref></p>
        <p>There are many treatments for the condition, with variable results. It can take up to months before the patient notices an improvement, and the effects may be only marginal.&#x000a0;Patients must understand that the condition may not be cured, and symptoms may return anytime. However, with proper treatment, there can be significant improvements in symptoms and quality of life.</p>
      </sec>
      <sec id="article-132252.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Recent evidence suggests that many men diagnosed with chronic prostatitis/chronic pelvic pain syndrome may have&#x000a0;IC/BPS as the symptoms are very similar, and each is a diagnosis of exclusion.<xref ref-type="bibr" rid="article-132252.r3">[3]</xref><xref ref-type="bibr" rid="article-132252.r4">[4]</xref><xref ref-type="bibr" rid="article-132252.r5">[5]</xref><xref ref-type="bibr" rid="article-132252.r6">[6]</xref><xref ref-type="bibr" rid="article-132252.r7">[7]</xref></p>
        <p>Men diagnosed with&#x000a0;chronic prostatitis/chronic pelvic pain syndrome who fail to respond to the standard therapy for prostatitis and continue to have symptoms, including frequency, painful bladder filling, suprapubic discomfort, dysuria, urgency, or pelvic discomfort, should be considered for treatment of IC/BPS.<xref ref-type="bibr" rid="article-132252.r3">[3]</xref><xref ref-type="bibr" rid="article-132252.r4">[4]</xref><xref ref-type="bibr" rid="article-132252.r5">[5]</xref><xref ref-type="bibr" rid="article-132252.r6">[6]</xref><xref ref-type="bibr" rid="article-132252.r7">[7]</xref></p>
        <p>Pudendal neuralgia and nerve compression should also be considered when dealing with patients with IC/BPS symptoms, especially those unresponsive to conservative, oral, and intravesical therapies.<xref ref-type="bibr" rid="article-132252.r201">[202]</xref></p>
        <p>Pain management should be involved in the care of patients with IC/BPS who have ongoing chronic pain.</p>
        <p>Before progressing to invasive therapies when oral and intravesical instillations have failed, consider a trial of cyclosporine A, misoprostol (oral or intravesical), botulinum toxin A, or neuromodulation therapy.</p>
        <p>Failure of all non-invasive therapies should suggest a reconsideration of the underlying diagnosis.</p>
        <p>There is no need to wait for oral therapies to fail before starting intravesical instillations in appropriate cases.</p>
        <p>A number of urinary inflammatory biomarkers are increased in IC/BPS, such as&#x000a0;TNF-&#x003b1;, PGE2, IL-6, and IL-8, although the diagnostic and clinical utility of this finding still needs to be determined.<xref ref-type="bibr" rid="article-132252.r35">[35]</xref>&#x000a0;A clinically useful biomarker for IC/BPS is still awaiting discovery.<xref ref-type="bibr" rid="article-132252.r20">[20]</xref></p>
        <p>
<bold>Supplements</bold>
</p>
        <p>For most dietary supplements used for pelvic pain or IC/BPS, there is only very limited scientific data or proof of efficacy, but there is some interesting, if limited, favorable evidence:</p>
        <list list-type="bullet">
          <list-item>
            <p>L-arginine at a dose of 1,500 mg/day has been shown&#x000a0;to improve symptoms of IC/BPS by increasing urinary nitric oxide synthase activity in a preliminary randomized, double-blinded, placebo-controlled trial.&#x000a0;About half of the patients treated noted symptomatic improvement.<xref ref-type="bibr" rid="article-132252.r202">[203]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Omega-3 fatty acids and alpha lipoic acid are effective anti-oxidants and have shown some anti-inflammatory effects and pelvic pain relief.<xref ref-type="bibr" rid="article-132252.r203">[204]</xref><xref ref-type="bibr" rid="article-132252.r204">[205]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Quercetin is a bioflavonoid that may also help reduce inflammation by scavenging free radicals. It has shown some clinical activity in improving symptoms in IC/BPS in a limited study that was not placebo-controlled or randomized.<xref ref-type="bibr" rid="article-132252.r205">[206]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Calcium glycerophosphate should be taken before meals, especially before eating foods known to trigger an IC reaction. A survey by the Interstitial Cystitis Association reported that 75% of patients who tried the supplement thought it provided some symptomatic benefit. A 2001 prospective nonrandomized study of over 200 IC patients reported a benefit in &#x0003e;40% of participants.<xref ref-type="bibr" rid="article-132252.r206">[207]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>There are some anecdotal reports of a benefit from oral hyaluronic acid therapy, but no formal published studies exist.</p>
          </list-item>
        </list>
        <p>
<bold>Bladder Cocktails for Intravesical Instillation</bold>
</p>
        <p>Home bladder cocktail instillations done by the patient are preferred over office/clinic administration whenever possible.&#x000a0;</p>
        <p>A typical schedule might be weekly instillations until symptom control is reached. Then, the interval between instillations is slowly extended as tolerated.&#x000a0;</p>
        <p>Some experts recommend having&#x000a0;2 intravesical cocktail formulas available: one with DMSO and the other without. If the original cocktail selected appears to be losing effectiveness or is unacceptable for some reason, the second formula can be substituted. In this way, intravesical therapy is maintained as it remains the single most effective overall non-surgical treatment.</p>
        <p>While there is no accepted standard intravesical cocktail, several noted experts have published their own personal recipes:&#x000a0;</p>
        <p>Alkalinized Lidocaine Cocktail</p>
        <list list-type="bullet">
          <list-item>
            <p>Gentamicin 80 mg in 5 mL</p>
          </list-item>
          <list-item>
            <p>Heparin 10,000 IU in 10 mL</p>
          </list-item>
          <list-item>
            <p>Lidocaine 2% solution: 25 mL</p>
          </list-item>
          <list-item>
            <p>Sodium Bicarbonate 8.4%: 5 mL&#x02013;10 mL</p>
          </list-item>
          <list-item>
            <p>Schedule:&#x000a0;
<list list-type="bullet"><list-item><p>Weekly as needed in office/clinic.</p></list-item><list-item><p>Should be mixed immediately before intravesical instillation to avoid precipitation.</p></list-item><list-item><p>Increase the interval between instillations as symptoms improve.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Dimethylsulfoxide (DMSO) Cocktail</p>
        <list list-type="bullet">
          <list-item>
            <p>Gentamicin 80 mg in 5 mL</p>
          </list-item>
          <list-item>
            <p>Heparin 10,000 IU&#x02013;20,000 IU</p>
          </list-item>
          <list-item>
            <p>Rimso-50 (DMSO) 50 mL</p>
          </list-item>
          <list-item>
            <p>Sodium Bicarbonate 8.4%: 10 mL</p>
          </list-item>
          <list-item>
            <p>Triamcinolone 40 mg</p>
          </list-item>
          <list-item>
            <p>Schedule:
<list list-type="bullet"><list-item><p>Weekly as needed in the office/clinic.</p></list-item><list-item><p>Increase the interval between instillations as symptoms improve.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Robert Moldwin, MD&#x02014;Smith Institute for Urology &#x00026; Long Island Jewish Medical Center</p>
        <list list-type="bullet">
          <list-item>
            <p>Bupivacaine (Marcaine) 0.5% and Lidocaine jelly 2% in a 1:1 mixture: Total of 30 mL&#x02013;40 mL</p>
          </list-item>
          <list-item>
            <p>Heparin 10,000 IU&#x02013;20,000 IU</p>
          </list-item>
          <list-item>
            <p>Gentamicin 80 mg</p>
          </list-item>
          <list-item>
            <p>Triamcinolone 40 mg (Increase to 80 mg in patients with documented Hunner ulcer)</p>
          </list-item>
          <list-item>
            <p>Schedule:
<list list-type="bullet"><list-item><p>Weekly instillations in the office/clinic</p></list-item><list-item><p>May also be self-administered by patients at home up to&#x000a0;3 times weekly.</p></list-item><list-item><p>Increase the interval between instillations as symptoms improve.</p></list-item><list-item><p>Maximum symptom improvement is expected by&#x000a0;12 weeks.</p></list-item><list-item><p>If no longer effective, switch to &#x0201c;DMSO Cocktail.&#x0201d; May resume the above bupivacaine combination cocktail later if symptoms return.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Christopher Payne, MD &#x0201c;Payne Cocktail 1&#x0201d;</p>
        <list list-type="bullet">
          <list-item>
            <p>Bupivacaine (Marcaine) 0.5%: 10 mL</p>
          </list-item>
          <list-item>
            <p>Heparin 10,000 IU</p>
          </list-item>
          <list-item>
            <p>Schedule:
<list list-type="bullet"><list-item><p>Weekly instillations in the office/clinic.</p></list-item><list-item><p>May also be self-administered by patients at home as often as daily.</p></list-item><list-item><p>Increase the interval between instillations as symptoms improve.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Christopher Payne, MD &#x0201c;Payne Cocktail 2&#x0201d;</p>
        <list list-type="bullet">
          <list-item>
            <p>Bupivacaine (Marcaine) 0.5%: 10 mL</p>
          </list-item>
          <list-item>
            <p>Heparin 10,000 IU (Optional, may be reserved as separate instillation treatment)</p>
          </list-item>
          <list-item>
            <p>Hydrocortisone (Solu-Cortef) 100 mg</p>
          </list-item>
          <list-item>
            <p>Rimso-50 (DMSO): 50 mL</p>
          </list-item>
          <list-item>
            <p>Sodium Bicarbonate 8.4%: 5 mL</p>
          </list-item>
          <list-item>
            <p>Schedule:
<list list-type="bullet"><list-item><p>Weekly instillations of 30 to 50 mL for&#x000a0;6 to&#x000a0;8 weeks.</p></list-item><list-item><p>Increase the interval between instillations as symptoms improve.</p></list-item><list-item><p>Use B&#x00026;O suppositories if patients cannot hold the solution for at least 30 minutes.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Kristene Whitmore, MD&#x02014;Drexel University College of Medicine</p>
        <list list-type="bullet">
          <list-item>
            <p>Bupivacaine (Marcaine) 0.5%: 20 mL</p>
          </list-item>
          <list-item>
            <p>Gentamicin 80 mg: 5 mL of normal saline (Add for patients with a documented UTI within&#x000a0;3 months)</p>
          </list-item>
          <list-item>
            <p>Heparin 10,000 IU in 10 mL</p>
          </list-item>
          <list-item>
            <p>Hydrocortisone 100 mg: 5 mL of normal saline</p>
          </list-item>
          <list-item>
            <p>Sodium Bicarbonate 8.4%: 40 mL&#x02013;50 mL</p>
          </list-item>
          <list-item>
            <p>Schedule:
<list list-type="bullet"><list-item><p>Six weekly instillations. Should be administered during a premenstrual flare when possible.</p></list-item><list-item><p>Appropriate for patients who can self-catheterize and administer at home.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132252.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>IC/BPS&#x000a0;is a long-term, chronic condition that&#x000a0;can significantly negatively affect the patient's quality of life and physical, psychological, and social health. The condition is often not easily managed by 1 intervention alone, and many physical and psychological comorbidities often exist. Therefore, an interprofessional team approach involving different specialties is best suited to offer&#x000a0;optimal care to the patient.</p>
        <p>Urologists, pain management specialists, gynecologists, urogynecologists, primary care physicians, specialist nurses, mental health professionals, pharmacists, dieticians, social workers, physical therapists,&#x000a0;and other healthcare professionals all play crucial roles in delivering comprehensive care.<xref ref-type="bibr" rid="article-132252.r160">[161]</xref><xref ref-type="bibr" rid="article-132252.r207">[208]</xref>&#x000a0;</p>
        <p>Healthcare professionals&#x000a0;must possess specialized skills in recognizing, diagnosing, and managing IC/BPS. This includes proficiency in conducting cystoscopy and urodynamics to confirm the diagnosis and a deep understanding of the latest treatment modalities and therapeutic options.</p>
        <p>Developing evidence-based treatment plans tailored to each patient's specific needs is vital. Strategies should encompass dietary modifications, physical therapy, and pharmacological interventions. Furthermore, clinicians must be well-versed in monitoring patient progress and adjusting treatment regimens accordingly.</p>
        <p>Effective communication among team members is paramount. Clinicians should exchange information about patient progress, potential complications, and treatment adjustments to ensure cohesive and comprehensive care. Collaboration fosters a holistic approach to addressing the physical and emotional aspects of&#x000a0;IC/BPS.</p>
        <p>IC/BPS&#x000a0;care is most effective when healthcare professionals collaborate to provide patient-centered, evidence-based care. The combined efforts of&#x000a0;an interprofessional team are critical for enhancing the quality of life and overall well-being of individuals living with IC/BPS.</p>
      </sec>
      <sec id="article-132252.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132252&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132252">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/interstitial-cystitis-bladder-pain-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=132252">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/132252/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=132252">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-132252.s17">
        <fig id="article-132252.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Normal Mucosa of the Bladder Wall. It is characterised by pale/pink appearance, lack of erythema, swellings, and relatively straight capillaries. Contributed by Mr O'Rourke, FRCS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="normal__mucosa" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-132252.s18">
        <fig id="article-132252.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Abnormal Mucosa Wall. This image shows capillary glomerulations. Contributed by Mr O'Rourke, FRCS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hunners__glomerulation1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-132252.s19">
        <fig id="article-132252.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Abnormal Bladder Mucosa, Showing a Hunner Ulcer. The erythematous mucosa with radiating capillaries towards a pale central ulcer is visualized here. Contributed by Mr O'Rourke, FRCS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hunners__ulcer" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-132252.s20">
        <fig id="article-132252.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Illustration of the Bladder Anatomy. An illustration of a classic Hunner ulcer located at the posterior bladder mucosa, where it is most commonly found. Contributed and Illustrated by Dr Ramiz Ahmed-Man, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Bladder__anatomy__and__Hunners__ulcer__by__Ram__xcropx" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-132252.s21">
        <title>References</title>
        <ref id="article-132252.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome.</article-title>
            <source>J Urol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>208</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-42</page-range>
            <pub-id pub-id-type="pmid">35536143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dmochowski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2009</year>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>274</fpage>
            <page-range>274-86</page-range>
            <pub-id pub-id-type="pmid">19260081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rothman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Krieger</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Bladder petechiae after cystoscopy and hydrodistension in men diagnosed with prostate pain.</article-title>
            <source>J Urol</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-5</page-range>
            <pub-id pub-id-type="pmid">9400442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forrest</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Interstitial cystitis, chronic nonbacterial prostatitis and chronic pelvic pain syndrome in men: a common and frequently identical clinical entity.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>172</volume>
            <issue>6 Pt 2</issue>
            <fpage>2561</fpage>
            <page-range>2561-2</page-range>
            <pub-id pub-id-type="pmid">15538208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forrest</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Vo</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Observations on the presentation, diagnosis, and treatment of interstitial cystitis in men.</article-title>
            <source>Urology</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6 Suppl 1</issue>
            <fpage>26</fpage>
            <page-range>26-9</page-range>
            <pub-id pub-id-type="pmid">11378046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Clauw</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kreder</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krieger</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landis</surname>
                <given-names>JR</given-names>
              </name>
              <collab>MAPP Research Network</collab>
            </person-group>
            <article-title>Comparison of baseline urological symptoms in men and women in the MAPP research cohort.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>May</month>
            <volume>193</volume>
            <issue>5</issue>
            <fpage>1554</fpage>
            <page-range>1554-8</page-range>
            <pub-id pub-id-type="pmid">25463989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arora</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Shoskes</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The enigma of men with interstitial cystitis/bladder pain syndrome.</article-title>
            <source>Transl Androl Urol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>668</fpage>
            <page-range>668-76</page-range>
            <pub-id pub-id-type="pmid">26813678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bogart</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
            </person-group>
            <article-title>Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>177</volume>
            <issue>2</issue>
            <fpage>450</fpage>
            <page-range>450-6</page-range>
            <pub-id pub-id-type="pmid">17222607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bolla</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Odeluga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Amraei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jetti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Histology, Bladder</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31082007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>LaGrange</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <chapter-title>Anatomy, Abdomen and Pelvis, Sphincter Urethrae</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">29494045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nassereddin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>LaGrange</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <chapter-title>Anatomy, Abdomen and Pelvis: Bladder Detrusor Muscle</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29489195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shermadou</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Anatomy, Abdomen and Pelvis: Bladder</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">30285360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome.</article-title>
            <source>Biomedicines</source>
            <year>2022</year>
            <month>Sep</month>
            <day>23</day>
            <volume>10</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">36289642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shie</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome.</article-title>
            <source>BJU Int</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>108</volume>
            <issue>2 Pt 2</issue>
            <fpage>E136</fpage>
            <page-range>E136-41</page-range>
            <pub-id pub-id-type="pmid">21166752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>e76779</fpage>
            <pub-id pub-id-type="pmid">24146927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyagi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Janicki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chancellor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chermansky</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in imaging and understanding interstitial cystitis.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">30473772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kairys</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Schmidt-Wilcke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Puiu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ichesco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Labus</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Martucci</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Apkarian</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Maravilla</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Clauw</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Increased brain gray matter in the primary somatosensory cortex is associated with increased pain and mood disturbance in patients with interstitial cystitis/painful bladder syndrome.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>193</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <page-range>131-7</page-range>
            <pub-id pub-id-type="pmid">25132239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilpatrick</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kutch</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Tillisch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Naliboff</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Labus</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Apkarian</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martucci</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Clauw</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Maravilla</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Alterations in resting state oscillations and connectivity in sensory and motor networks in women with interstitial cystitis/painful bladder syndrome.</article-title>
            <source>J Urol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>192</volume>
            <issue>3</issue>
            <fpage>947</fpage>
            <page-range>947-55</page-range>
            <pub-id pub-id-type="pmid">24681331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chetwood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ketamine cystitis: practical considerations in management.</article-title>
            <source>Scand J Urol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>482</fpage>
            <page-range>482-8</page-range>
            <pub-id pub-id-type="pmid">24779452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Argade</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chermansky</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tyagi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers for interstitial cystitis/painful bladder syndrome.</article-title>
            <source>Womens Health (Lond)</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-90</page-range>
            <pub-id pub-id-type="pmid">26696241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Buffington</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Dinis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis.</article-title>
            <source>Int J Womens Health</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>735</fpage>
            <page-range>735-44</page-range>
            <pub-id pub-id-type="pmid">26229509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gamper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Welter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eberhard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viereck</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis?</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>193</volume>
            <issue>6</issue>
            <fpage>1994</fpage>
            <page-range>1994-2000</page-range>
            <pub-id pub-id-type="pmid">25596361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ackerman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>UJ</given-names>
              </name>
              <name>
                <surname>Jellison</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>LV</given-names>
              </name>
            </person-group>
            <article-title>MRI suggests increased tonicity of the levator ani in women with interstitial cystitis/bladder pain syndrome.</article-title>
            <source>Int Urogynecol J</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-83</page-range>
            <pub-id pub-id-type="pmid">26231233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Suttorp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bogart</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Stoto</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Eggers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nyberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States.</article-title>
            <source>J Urol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>186</volume>
            <issue>2</issue>
            <fpage>540</fpage>
            <page-range>540-4</page-range>
            <pub-id pub-id-type="pmid">21683389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suskind</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ewing</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Suttorp</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
            </person-group>
            <article-title>The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>189</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-5</page-range>
            <pub-id pub-id-type="pmid">23164386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curhan</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Speizer</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Stampfer</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of interstitial cystitis: a population based study.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>161</volume>
            <issue>2</issue>
            <fpage>549</fpage>
            <page-range>549-52</page-range>
            <pub-id pub-id-type="pmid">9915446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konkle</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Hilton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Suttorp</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Clauw</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study.</article-title>
            <source>J Urol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>187</volume>
            <issue>2</issue>
            <fpage>508</fpage>
            <page-range>508-12</page-range>
            <pub-id pub-id-type="pmid">22177158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Meenan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>O'Keeffe Rosetti</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of interstitial cystitis symptoms in a managed care population.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>174</volume>
            <issue>2</issue>
            <fpage>576</fpage>
            <page-range>576-80</page-range>
            <pub-id pub-id-type="pmid">16006901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bade</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rijcken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mensink</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Interstitial cystitis in The Netherlands: prevalence, diagnostic criteria and therapeutic preferences.</article-title>
            <source>J Urol</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>154</volume>
            <issue>6</issue>
            <fpage>2035</fpage>
            <page-range>2035-7; discussion 2037-8</page-range>
            <pub-id pub-id-type="pmid">7500452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Recommendations to the primary care practitioners and the patients for managing pelvic pain, especially in painful bladder syndrome for early and better prognosis.</article-title>
            <source>J Exerc Rehabil</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>251</fpage>
            <page-range>251-4</page-range>
            <pub-id pub-id-type="pmid">26535214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis.</article-title>
            <source>Tzu Chi Med J</source>
            <year>2023</year>
            <season>Jan-Mar</season>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-37</page-range>
            <pub-id pub-id-type="pmid">36866354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lopez</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mang&#x00131;r</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Current standard of care in treatment of bladder pain syndrome/interstitial cystitis.</article-title>
            <source>Ther Adv Urol</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>13</volume>
            <fpage>17562872211022478</fpage>
            <pub-id pub-id-type="pmid">34178118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johansson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Fall</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and spectrum of light microscopic changes in interstitial cystitis.</article-title>
            <source>J Urol</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>143</volume>
            <issue>6</issue>
            <fpage>1118</fpage>
            <page-range>1118-24</page-range>
            <pub-id pub-id-type="pmid">2342171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shie</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome.</article-title>
            <source>Urology</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>484.e7</fpage>
            <page-range>484.e7-13</page-range>
            <pub-id pub-id-type="pmid">22310775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Oct</month>
            <day>10</day>
            <volume>23</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">36233356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birder</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of interstitial cystitis.</article-title>
            <source>Int J Urol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>26 Suppl 1</volume>
            <fpage>12</fpage>
            <page-range>12-15</page-range>
            <pub-id pub-id-type="pmid">31144735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wen</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Risks of interstitial cystitis among patients with systemic lupus erythematosus: A population-based cohort study.</article-title>
            <source>Int J Urol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>897</fpage>
            <page-range>897-902</page-range>
            <pub-id pub-id-type="pmid">31311067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yueh</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Risk of Autoimmune Diseases in Patients With Interstitial Cystitis/Bladder Pain Syndrome: A Nationwide Population-Based Study in Taiwan.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>747098</fpage>
            <pub-id pub-id-type="pmid">34616760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darrieutort-Laffite</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hayem</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saraux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Guern</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Le Jeunne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pu&#x000e9;chal</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Sj&#x000f6;gren's syndrome complicated by interstitial cystitis: A case series and literature review.</article-title>
            <source>Joint Bone Spine</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>82</volume>
            <issue>4</issue>
            <fpage>245</fpage>
            <page-range>245-50</page-range>
            <pub-id pub-id-type="pmid">25680227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tripp</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Pontari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moldwin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Doggweiler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nordling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome.</article-title>
            <source>J Urol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>184</volume>
            <issue>4</issue>
            <fpage>1358</fpage>
            <page-range>1358-63</page-range>
            <pub-id pub-id-type="pmid">20719340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira E Silva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rom&#x000e3;o</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Neves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brites</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Canh&#x000e3;o</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Palma Dos Reis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pereira da Silva</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sj&#x000f6;gren syndrome.</article-title>
            <source>Lupus</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-33</page-range>
            <pub-id pub-id-type="pmid">30419773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanter</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Komesu</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Qaedan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jeppson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Dunivan</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Cichowski</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Mindfulness-based stress reduction as a novel treatment for interstitial cystitis/bladder pain syndrome: a randomized controlled trial.</article-title>
            <source>Int Urogynecol J</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>1705</fpage>
            <page-range>1705-1711</page-range>
            <pub-id pub-id-type="pmid">27116196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Koziol</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Natural history of interstitial cystitis in 274 patients receiving sulfated polysaccharide therapy.</article-title>
            <source>Urology</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>1133</fpage>
            <page-range>1133-9</page-range>
            <pub-id pub-id-type="pmid">10367841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lutgendorf</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kreder</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Rothrock</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Ratliff</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Stress and symptomatology in patients with interstitial cystitis: a laboratory stress model.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>164</volume>
            <issue>4</issue>
            <fpage>1265</fpage>
            <page-range>1265-9</page-range>
            <pub-id pub-id-type="pmid">10992377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pierce</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Christianson</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Stress and chronic pelvic pain.</article-title>
            <source>Prog Mol Biol Transl Sci</source>
            <year>2015</year>
            <volume>131</volume>
            <fpage>509</fpage>
            <page-range>509-35</page-range>
            <pub-id pub-id-type="pmid">25744684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lovick</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Central control of visceral pain and urinary tract function.</article-title>
            <source>Auton Neurosci</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>200</volume>
            <fpage>35</fpage>
            <page-range>35-42</page-range>
            <pub-id pub-id-type="pmid">26905459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dupont</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Spitsbergen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Steers</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Histological and neurotrophic changes triggered by varying models of bladder inflammation.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>166</volume>
            <issue>3</issue>
            <fpage>1111</fpage>
            <page-range>1111-8</page-range>
            <pub-id pub-id-type="pmid">11490308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynes</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Shortliffe</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Stamey</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>The histology of interstitial cystitis.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>969</fpage>
            <page-range>969-76</page-range>
            <pub-id pub-id-type="pmid">2403198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes among Patients with Interstitial Cystitis/Bladder Pain Syndrome: An Investigation of the European Society for the Study of Interstitial Cystitis Histopathological Classification.</article-title>
            <source>J Urol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>205</volume>
            <issue>1</issue>
            <fpage>226</fpage>
            <page-range>226-235</page-range>
            <pub-id pub-id-type="pmid">32856961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Update on the Pathology and Diagnosis of Interstitial Cystitis/Bladder Pain Syndrome: A Review.</article-title>
            <source>Int Neurourol J</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-7</page-range>
            <pub-id pub-id-type="pmid">27032552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Natale</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Campagna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marturano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caramazza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Panico</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vacca</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torcia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cervigni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scambia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ercoli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Is There a Role for Bladder Biopsy in the Diagnosis of Non-Hunner Lesions Interstitial Cystitis?</article-title>
            <source>Urol Int</source>
            <year>2023</year>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-262</page-range>
            <pub-id pub-id-type="pmid">35896088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diggs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Langenberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Assessing urgency in interstitial cystitis/painful bladder syndrome.</article-title>
            <source>Urology</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>210</fpage>
            <page-range>210-4</page-range>
            <pub-id pub-id-type="pmid">17275075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Litwin</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>McNaughton-Collins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Landis</surname>
                <given-names>JR</given-names>
              </name>
              <collab>Urologic Pelvic Pain Collaborative Research Network</collab>
            </person-group>
            <article-title>Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women.</article-title>
            <source>Urology</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>983</fpage>
            <page-range>983-7, quiz 987.e1-3</page-range>
            <pub-id pub-id-type="pmid">19800663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r54">
          <label>54</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ballstaedt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Woodbury</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Bladder Post Void Residual Volume</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">30969661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siltberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Victor</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Frequency/volume chart: the basic tool for investigating urinary symptoms.</article-title>
            <source>Acta Obstet Gynecol Scand Suppl</source>
            <year>1997</year>
            <volume>166</volume>
            <fpage>24</fpage>
            <page-range>24-7</page-range>
            <pub-id pub-id-type="pmid">9253374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrams</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klevmark</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Frequency volume charts: an indispensable part of lower urinary tract assessment.</article-title>
            <source>Scand J Urol Nephrol Suppl</source>
            <year>1996</year>
            <volume>179</volume>
            <fpage>47</fpage>
            <page-range>47-53</page-range>
            <pub-id pub-id-type="pmid">8908664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Mental health diagnoses in patients with interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome: a case/control study.</article-title>
            <source>J Urol</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>180</volume>
            <issue>4</issue>
            <fpage>1378</fpage>
            <page-range>1378-82</page-range>
            <pub-id pub-id-type="pmid">18707716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barocas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Kobashi</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith-Bindman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Souter</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Microhematuria: AUA/SUFU Guideline.</article-title>
            <source>J Urol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>204</volume>
            <issue>4</issue>
            <fpage>778</fpage>
            <page-range>778-786</page-range>
            <pub-id pub-id-type="pmid">32698717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erickson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kunselman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Bentley</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Rovner</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Demers</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Keay</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Changes in urine markers and symptoms after bladder distention for interstitial cystitis.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>177</volume>
            <issue>2</issue>
            <fpage>556</fpage>
            <page-range>556-60</page-range>
            <pub-id pub-id-type="pmid">17222633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Novicki</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Interstitial cystitis in men.</article-title>
            <source>Urology</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>621</fpage>
            <page-range>621-4</page-range>
            <pub-id pub-id-type="pmid">9763081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forrest</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Nickel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Moldwin</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Chronic prostatitis/chronic pelvic pain syndrome and male interstitial cystitis: enigmas and opportunities.</article-title>
            <source>Urology</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4 Suppl</issue>
            <fpage>60</fpage>
            <page-range>60-3</page-range>
            <pub-id pub-id-type="pmid">17462482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Zupkas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Intravesical potassium sensitivity in patients with interstitial cystitis and urethral syndrome.</article-title>
            <source>Urology</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>428</fpage>
            <page-range>428-32; discussion 432-3</page-range>
            <pub-id pub-id-type="pmid">11248610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r63">
          <label>63</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Antolak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feloney</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Soon-Sutton</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <chapter-title>Pudendal Neuralgia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">32965917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Niimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nomiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Igawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kume</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Homma</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Clinical characterization of interstitial cystitis/bladder pain syndrome in women based on the presence or absence of Hunner lesions and glomerulations.</article-title>
            <source>Low Urin Tract Symptoms</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <page-range>139-143</page-range>
            <pub-id pub-id-type="pmid">32830459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Using Urine Biomarkers to Differentiate Bladder Dysfunctions in Women with Sensory Bladder Disorders.</article-title>
            <source>Int J Mol Sci</source>
            <year>2024</year>
            <month>Aug</month>
            <day>29</day>
            <volume>25</volume>
            <issue>17</issue>
            <pub-id pub-id-type="pmid">39273307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vetter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Clinical Presentation of Urologic Chronic Pelvic Pain Syndrome (UCPPS) Varies With Presenting Age - Implication on Patient Evaluation.</article-title>
            <source>Urology</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>158</volume>
            <fpage>66</fpage>
            <page-range>66-73</page-range>
            <pub-id pub-id-type="pmid">34302833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wennevik</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Meijlink</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hanno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nordling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Role of Glomerulations in Bladder Pain Syndrome: A Review.</article-title>
            <source>J Urol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>195</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-25</page-range>
            <pub-id pub-id-type="pmid">26318984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ronstrom</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Presenting an atlas of Hunner lesions in interstitial cystitis which can be identified with office cystoscopy.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>2394</fpage>
            <page-range>2394-2400</page-range>
            <pub-id pub-id-type="pmid">32902893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ko</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Efficacy Between Transurethral Coagulation and Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients: A Prospective Randomized Controlled Trial.</article-title>
            <source>Eur Urol</source>
            <year>2020</year>
            <month>May</month>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>644</fpage>
            <page-range>644-651</page-range>
            <pub-id pub-id-type="pmid">31959549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peeker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aldenborg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fall</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Complete transurethral resection of ulcers in classic interstitial cystitis.</article-title>
            <source>Int Urogynecol J Pelvic Floor Dysfunct</source>
            <year>2000</year>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>290</fpage>
            <page-range>290-5</page-range>
            <pub-id pub-id-type="pmid">11052564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sairanen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tammela</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Leppilahti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Multanen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paananen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lehtoranta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ruutu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>174</volume>
            <issue>6</issue>
            <fpage>2235</fpage>
            <page-range>2235-8</page-range>
            <pub-id pub-id-type="pmid">16280777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tissot</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Diokno</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>A referral center's experience with transitional cell carcinoma misdiagnosed as interstitial cystitis.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>172</volume>
            <issue>2</issue>
            <fpage>478</fpage>
            <page-range>478-80</page-range>
            <pub-id pub-id-type="pmid">15247708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The diagnostic and therapeutic efficacy of cystoscopy with hydrodistension and random biopsies in clinically suspected interstitial cystitis/bladder pain syndrome.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>265</volume>
            <fpage>156</fpage>
            <page-range>156-161</page-range>
            <pub-id pub-id-type="pmid">34492610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sholan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical manifestations and results of cystoscopy in women with interstitial cystitis/bladder pain syndrome.</article-title>
            <source>North Clin Istanb</source>
            <year>2020</year>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>417</fpage>
            <page-range>417-424</page-range>
            <pub-id pub-id-type="pmid">33163875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grover</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tewari</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Te</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Role of inflammation in bladder function and interstitial cystitis.</article-title>
            <source>Ther Adv Urol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-33</page-range>
            <pub-id pub-id-type="pmid">21789096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FitzGerald</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lukacz</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Nickel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hanno</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kreder</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Burks</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kotarinos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fortman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mason-Cover</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Odabachian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sanfield</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huestis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tata</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Dugan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bewyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anaeme</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Featherstone</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Halle-Podell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Landis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Propert</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Nyberg</surname>
                <given-names>LM</given-names>
              </name>
              <collab>Interstitial Cystitis Collaborative Research Network</collab>
            </person-group>
            <article-title>Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness.</article-title>
            <source>J Urol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>187</volume>
            <issue>6</issue>
            <fpage>2113</fpage>
            <page-range>2113-8</page-range>
            <pub-id pub-id-type="pmid">22503015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>166</volume>
            <issue>6</issue>
            <fpage>2226</fpage>
            <page-range>2226-31</page-range>
            <pub-id pub-id-type="pmid">11696740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haegerich</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Apr</month>
            <day>19</day>
            <volume>315</volume>
            <issue>15</issue>
            <fpage>1624</fpage>
            <page-range>1624-45</page-range>
            <pub-id pub-id-type="pmid">26977696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos</surname>
                <given-names>TGD</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>IAS</given-names>
              </name>
              <name>
                <surname>Nygaard</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Schreiner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Systematic Review of Oral Therapy for the Treatment of Symptoms of Bladder Pain Syndrome: The Brazilian Guidelines.</article-title>
            <source>Rev Bras Ginecol Obstet</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-102</page-range>
            <pub-id pub-id-type="pmid">29241263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vollstedt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tennyson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hasenau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCartney</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilleran</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Evidence for Early Cyclosporine Treatment for Hunner Lesion Interstitial Cystitis.</article-title>
            <source>Female Pelvic Med Reconstr Surg</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e5</page-range>
            <pub-id pub-id-type="pmid">34608034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chermansky</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Guirguis</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic Management of Interstitial Cystitis/Bladder Pain Syndrome.</article-title>
            <source>Urol Clin North Am</source>
            <year>2022</year>
            <month>May</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-282</page-range>
            <pub-id pub-id-type="pmid">35428433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r82">
          <label>82</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Thour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marwaha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Amitriptyline</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30725910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Ophoven</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pokupic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heinecke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hertle</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>172</volume>
            <issue>2</issue>
            <fpage>533</fpage>
            <page-range>533-6</page-range>
            <pub-id pub-id-type="pmid">15247722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foster</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Hanno</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Nickel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Burks</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Kreder</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lukacz</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Cen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Landis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Propert</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Nyberg</surname>
                <given-names>LM</given-names>
              </name>
              <collab>Interstitial Cystitis Collaborative Research Network</collab>
            </person-group>
            <article-title>Effect of amitriptyline on symptoms in treatment na&#x000ef;ve patients with interstitial cystitis/painful bladder syndrome.</article-title>
            <source>J Urol</source>
            <year>2010</year>
            <month>May</month>
            <volume>183</volume>
            <issue>5</issue>
            <fpage>1853</fpage>
            <page-range>1853-8</page-range>
            <pub-id pub-id-type="pmid">20303115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abat</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Altunkol</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f6;kalp</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The effect of intravesical cocktail therapy combined with low-dose amitriptyline on primary bladder pain syndrome.</article-title>
            <source>Int Urogynecol J</source>
            <year>2022</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>1225</fpage>
            <page-range>1225-1230</page-range>
            <pub-id pub-id-type="pmid">34977954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dasgupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Womack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blackford</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cimetidine in painful bladder syndrome: a histopathological study.</article-title>
            <source>BJU Int</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-6</page-range>
            <pub-id pub-id-type="pmid">11488726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r87">
          <label>87</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pino</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Azer</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <chapter-title>Cimetidine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31334975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thilagarajah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Witherow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial.</article-title>
            <source>BJU Int</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-12</page-range>
            <pub-id pub-id-type="pmid">11167643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Cimetidine in treatment of interstitial cystitis.</article-title>
            <source>Urology</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>1088</fpage>
            <pub-id pub-id-type="pmid">7771018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forrest</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers.</article-title>
            <source>J Urol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>188</volume>
            <issue>4</issue>
            <fpage>1186</fpage>
            <page-range>1186-91</page-range>
            <pub-id pub-id-type="pmid">22901569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis.</article-title>
            <source>Int Urogynecol J</source>
            <year>2021</year>
            <month>May</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>1129</fpage>
            <page-range>1129-1141</page-range>
            <pub-id pub-id-type="pmid">33638677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r92">
          <label>92</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tapia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Zito</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <chapter-title>Cyclosporine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">29494057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bri&#x000e8;re</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bouchard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gareau Labelle</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>A pilot study on oral cyclosporine A in association with fulguration for the treatment of interstitial cystitis with Hunner's lesions.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>1498</fpage>
            <page-range>1498-1504</page-range>
            <pub-id pub-id-type="pmid">35731015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Speer</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Mushkbar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erbele</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Chronic Pelvic Pain in Women.</article-title>
            <source>Am Fam Physician</source>
            <year>2016</year>
            <month>Mar</month>
            <day>01</day>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>380</fpage>
            <page-range>380-7</page-range>
            <pub-id pub-id-type="pmid">26926975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Interstitial cystitis and the potential role of gabapentin.</article-title>
            <source>South Med J</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>238</fpage>
            <page-range>238-42</page-range>
            <pub-id pub-id-type="pmid">10701800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chancellor</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain.</article-title>
            <source>Tech Urol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-9</page-range>
            <pub-id pub-id-type="pmid">11272678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chancellor</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin for overactive bladder and nocturia after anticholinergic failure.</article-title>
            <source>Int Braz J Urol</source>
            <year>2004</year>
            <season>Jul-Aug</season>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>275</fpage>
            <page-range>275-8</page-range>
            <pub-id pub-id-type="pmid">15679954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r98">
          <label>98</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yasaei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Katta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Gabapentin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">29630280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sant</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Propert</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hanno</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Burks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Culkin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Diokno</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Landis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Madigan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Messing</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Theoharides</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wein</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Steers</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Nyberg</surname>
                <given-names>LM</given-names>
              </name>
              <collab>Interstitial Cystitis Clinical Trials Group</collab>
            </person-group>
            <article-title>A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>170</volume>
            <issue>3</issue>
            <fpage>810</fpage>
            <page-range>810-5</page-range>
            <pub-id pub-id-type="pmid">12913705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minogiannis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>El-Mansoury</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Betances</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sant</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Theoharides</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Hydroxyzine inhibits neurogenic bladder mast cell activation.</article-title>
            <source>Int J Immunopharmacol</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>553</fpage>
            <page-range>553-63</page-range>
            <pub-id pub-id-type="pmid">9839659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dobberfuhl</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>1958</fpage>
            <page-range>1958-1966</page-range>
            <pub-id pub-id-type="pmid">35607890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loloi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clearwater</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suadicani</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Medical Treatment of Overactive Bladder.</article-title>
            <source>Urol Clin North Am</source>
            <year>2022</year>
            <month>May</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-261</page-range>
            <pub-id pub-id-type="pmid">35428431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holm-Bentzen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nerstr&#x000f8;m</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lose</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Krarup</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Feggetter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barnard</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease.</article-title>
            <source>J Urol</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>138</volume>
            <issue>3</issue>
            <fpage>503</fpage>
            <page-range>503-7</page-range>
            <pub-id pub-id-type="pmid">2442415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Herschorn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whitmore</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Baseman</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>193</volume>
            <issue>3</issue>
            <fpage>857</fpage>
            <page-range>857-62</page-range>
            <pub-id pub-id-type="pmid">25245489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulholland</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Hanno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Sant</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Staskin</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study.</article-title>
            <source>Urology</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>552</fpage>
            <page-range>552-8</page-range>
            <pub-id pub-id-type="pmid">1693797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Childs</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hanno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sant</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>Sep</month>
            <volume>150</volume>
            <issue>3</issue>
            <fpage>845</fpage>
            <page-range>845-8</page-range>
            <pub-id pub-id-type="pmid">7688432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Mulholland</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Successful therapy of interstitial cystitis with pentosanpolysulfate.</article-title>
            <source>J Urol</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>138</volume>
            <issue>3</issue>
            <fpage>513</fpage>
            <page-range>513-6</page-range>
            <pub-id pub-id-type="pmid">2442417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanno</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Analysis of long-term Elmiron therapy for interstitial cystitis.</article-title>
            <source>Urology</source>
            <year>1997</year>
            <month>May</month>
            <volume>49</volume>
            <issue>5A Suppl</issue>
            <fpage>93</fpage>
            <page-range>93-9</page-range>
            <pub-id pub-id-type="pmid">9146008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r109">
          <label>109</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Margines</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <chapter-title>Pentosan Polysulfate Maculopathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">36944010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearce</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium.</article-title>
            <source>Ophthalmology</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>125</volume>
            <issue>11</issue>
            <fpage>1793</fpage>
            <page-range>1793-1802</page-range>
            <pub-id pub-id-type="pmid">29801663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohning</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Skopis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Levinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kasi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of Pentosan Polysulfate Sodium-Associated Maculopathy and Similarities With Other Maculopathies Commonly Managed in a Retina Practice.</article-title>
            <source>J Vitreoretin Dis</source>
            <year>2022</year>
            <season>Mar-Apr</season>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-110</page-range>
            <pub-id pub-id-type="pmid">37008666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanif</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Armenti</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Igelman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Jayasundera</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Pennesi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Khurana</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Foote</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>O'Keefe</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Flaxel</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy: A Multicenter Study.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>137</volume>
            <issue>11</issue>
            <fpage>1275</fpage>
            <page-range>1275-1282</page-range>
            <pub-id pub-id-type="pmid">31486843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>VanderBeek</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>104</volume>
            <issue>8</issue>
            <fpage>1093</fpage>
            <page-range>1093-1097</page-range>
            <pub-id pub-id-type="pmid">31694837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukhopadhyay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gehrs</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Folk</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kreder</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Age-Related Macular Degeneration Masquerade: A Review of Pentosan Polysulfate Maculopathy and Implications for Clinical Practice.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <string-date>2022 Mar-Apr 01</string-date>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>100</fpage>
            <page-range>100-110</page-range>
            <pub-id pub-id-type="pmid">35533330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Priluck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Pentosan polysulfate maculopathy: a brief primer for general practitioners, ophthalmologists, optometrists and urologists.</article-title>
            <source>Med J Aust</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>218</volume>
            <issue>8</issue>
            <fpage>348</fpage>
            <page-range>348-350</page-range>
            <pub-id pub-id-type="pmid">36990107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Lindeke-Myers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate Use.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2023</year>
            <month>Mar</month>
            <day>01</day>
            <volume>141</volume>
            <issue>3</issue>
            <fpage>260</fpage>
            <page-range>260-266</page-range>
            <pub-id pub-id-type="pmid">36729449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mak</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Furrer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sahai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raison</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation in the management of chronic pelvic pain: A systematic review and meta-analysis.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>822</fpage>
            <page-range>822-836</page-range>
            <pub-id pub-id-type="pmid">36877182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r118">
          <label>118</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Feloney</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Stauss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Sacral Neuromodulation</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">33620828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Konstandt</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation decreases narcotic requirements in refractory interstitial cystitis.</article-title>
            <source>BJU Int</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>93</volume>
            <issue>6</issue>
            <fpage>777</fpage>
            <page-range>777-9</page-range>
            <pub-id pub-id-type="pmid">15049989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alkis</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Aras</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sevim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kartal</surname>
                <given-names>&#x00130;G</given-names>
              </name>
              <name>
                <surname>S&#x000f6;nmez</surname>
                <given-names>OY</given-names>
              </name>
              <name>
                <surname>&#x00130;velik</surname>
                <given-names>H&#x00130;</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of transcutaneous tibial nerve stimulation in the treatment of bladder pain syndrome.</article-title>
            <source>Curr Urol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-87</page-range>
            <pub-id pub-id-type="pmid">36570363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padilla-Fern&#x000e1;ndez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Hern&#x000e1;ndez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Castro-D&#x000ed;az</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Current role of neuromodulation in bladder pain syndrome/interstitial cystitis.</article-title>
            <source>Ther Adv Urol</source>
            <year>2022</year>
            <season>Jan-Dec</season>
            <volume>14</volume>
            <fpage>17562872221135941</fpage>
            <pub-id pub-id-type="pmid">36438605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elhilali</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Khaled</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kashiwabara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Elzayat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Corcos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation: long-term experience of one center.</article-title>
            <source>Urology</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>1114</fpage>
            <page-range>1114-7</page-range>
            <pub-id pub-id-type="pmid">15913732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sogutdelen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Citamak</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of intravesical cocktail therapy with or without dimethyl sulphoxide in interstitial cystitis.</article-title>
            <source>Cent European J Urol</source>
            <year>2022</year>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-304</page-range>
            <pub-id pub-id-type="pmid">36381159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perez-Marrero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Emerson</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Feltis</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>A controlled study of dimethyl sulfoxide in interstitial cystitis.</article-title>
            <source>J Urol</source>
            <year>1988</year>
            <month>Jul</month>
            <volume>140</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-9</page-range>
            <pub-id pub-id-type="pmid">3288775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moss</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Chill</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Gafni-Kane</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS).</article-title>
            <source>Neurourol Urodyn</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>615</fpage>
            <page-range>615-622</page-range>
            <pub-id pub-id-type="pmid">36747494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r126">
          <label>126</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Homma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tomoe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Otsuka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kitta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Masumori</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Niimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitsui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nanri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Namima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sekiguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kajiwara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ameda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muraki</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Shishido</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kageyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kokura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okazoe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamanishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohinata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: A multicenter, randomized, double-blind, placebo-controlled, clinical study.</article-title>
            <source>Int J Urol</source>
            <year>2021</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>545</fpage>
            <page-range>545-553</page-range>
            <pub-id pub-id-type="pmid">33580603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r127">
          <label>127</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hung</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail.</article-title>
            <source>Int Urogynecol J</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1533</fpage>
            <page-range>1533-9</page-range>
            <pub-id pub-id-type="pmid">22426874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lotsof</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Botros</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tomezsko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gafni-Kane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Botros</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study.</article-title>
            <source>Int Urogynecol J</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>1335</fpage>
            <page-range>1335-1340</page-range>
            <pub-id pub-id-type="pmid">28150028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomoe</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective?</article-title>
            <source>Transl Androl Urol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>600</fpage>
            <page-range>600-4</page-range>
            <pub-id pub-id-type="pmid">26816859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Housley</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lebow</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treatment of interstitial cystitis with intravesical heparin.</article-title>
            <source>Br J Urol</source>
            <year>1994</year>
            <month>May</month>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>504</fpage>
            <page-range>504-7</page-range>
            <pub-id pub-id-type="pmid">8012771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r131">
          <label>131</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Zupkas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Proctor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koziol</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giesing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lakin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Garner</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis.</article-title>
            <source>J Sex Med</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>207</fpage>
            <page-range>207-12</page-range>
            <pub-id pub-id-type="pmid">22082303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Koziol</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Proctor</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Zupkas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Argade</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms.</article-title>
            <source>Can J Urol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>7739</fpage>
            <page-range>7739-44</page-range>
            <pub-id pub-id-type="pmid">25891339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Digesu</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tailor</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhide</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Khullar</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?</article-title>
            <source>Int Urogynecol J</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>1387</fpage>
            <page-range>1387-1392</page-range>
            <pub-id pub-id-type="pmid">32358624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r134">
          <label>134</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madurga Patuel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-L&#x000f3;pez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Resel Folkersma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Machado Fern&#x000e1;ndez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Adot Zurbano</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bonillo</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
              <name>
                <surname>Vozmediano Chicharro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zubiaur L&#x000ed;bano</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Recommendations on the use of intravesical hyaluronic acid instillations in bladder pain syndrome.</article-title>
            <source>Actas Urol Esp (Engl Ed)</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>131</fpage>
            <page-range>131-137</page-range>
            <pub-id pub-id-type="pmid">35256323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r135">
          <label>135</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>FQ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The effects of intravesical therapy with hyaluronic acid for painful bladder syndrome: Preliminary Chinese experience and systematic review.</article-title>
            <source>Taiwan J Obstet Gynecol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>240</fpage>
            <page-range>240-7</page-range>
            <pub-id pub-id-type="pmid">26166334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r136">
          <label>136</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pyo</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Systematic Review and Meta-Analysis of Intravesical Hyaluronic Acid and Hyaluronic Acid/Chondroitin Sulfate Instillation for Interstitial Cystitis/Painful Bladder Syndrome.</article-title>
            <source>Cell Physiol Biochem</source>
            <year>2016</year>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>1618</fpage>
            <page-range>1618-25</page-range>
            <pub-id pub-id-type="pmid">27627755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r137">
          <label>137</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rooney</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Quinlan</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis.</article-title>
            <source>Acta Biomater</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>19</volume>
            <fpage>66</fpage>
            <page-range>66-75</page-range>
            <pub-id pub-id-type="pmid">25818949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r138">
          <label>138</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Urinary and psychological outcomes in women with interstitial cystitis/bladder pain syndrome following hyaluronic acid treatment.</article-title>
            <source>Taiwan J Obstet Gynecol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>360</fpage>
            <page-range>360-363</page-range>
            <pub-id pub-id-type="pmid">29880165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r139">
          <label>139</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hung</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronic acid improves pain symptoms more than bladder storage symptoms in women with interstitial cystitis.</article-title>
            <source>Taiwan J Obstet Gynecol</source>
            <year>2019</year>
            <month>May</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>417</fpage>
            <page-range>417-422</page-range>
            <pub-id pub-id-type="pmid">31122535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r140">
          <label>140</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henry</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Beyond a Simple Anesthetic Effect: Lidocaine in the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome.</article-title>
            <source>Urology</source>
            <year>2015</year>
            <month>May</month>
            <volume>85</volume>
            <issue>5</issue>
            <fpage>1025</fpage>
            <page-range>1025-1033</page-range>
            <pub-id pub-id-type="pmid">25917728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r141">
          <label>141</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Joo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>NF-&#x003ba;B signaling in inflammation.</article-title>
            <source>Signal Transduct Target Ther</source>
            <year>2017</year>
            <volume>2</volume>
            <fpage>17023</fpage>
            <page-range>17023-</page-range>
            <pub-id pub-id-type="pmid">29158945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r142">
          <label>142</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Mageed</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bajwa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shenassa</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Human</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ghoniem</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>NF-kappaB-dependent gene expression of proinflammatory cytokines in T24 cells: possible role in interstitial cystitis.</article-title>
            <source>Urol Res</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>300</fpage>
            <page-range>300-5</page-range>
            <pub-id pub-id-type="pmid">14574533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r143">
          <label>143</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Longstreth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jamali</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Misoprostol therapeutics revisited.</article-title>
            <source>Pharmacotherapy</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-73</page-range>
            <pub-id pub-id-type="pmid">11191738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r144">
          <label>144</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyagi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chancellor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Groat</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sustained intravesical drug delivery using thermosensitive hydrogel.</article-title>
            <source>Pharm Res</source>
            <year>2004</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>832</fpage>
            <page-range>832-7</page-range>
            <pub-id pub-id-type="pmid">15180342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r145">
          <label>145</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Engelmann</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>IJ</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy.</article-title>
            <source>J Urol</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>136</volume>
            <issue>2</issue>
            <fpage>497</fpage>
            <page-range>497-500</page-range>
            <pub-id pub-id-type="pmid">3090278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r146">
          <label>146</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Clinical response to an oral prostaglandin analogue in patients with interstitial cystitis.</article-title>
            <source>Eur Urol</source>
            <year>1998</year>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-6</page-range>
            <pub-id pub-id-type="pmid">9676414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r147">
          <label>147</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardenas-Trowers</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Dotson</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Houlette</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Gaskins</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Bladder Instillations With Triamcinolone Acetonide for Interstitial Cystitis-Bladder Pain Syndrome: A Randomized Controlled Trial.</article-title>
            <source>Obstet Gynecol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>137</volume>
            <issue>5</issue>
            <fpage>810</fpage>
            <page-range>810-819</page-range>
            <pub-id pub-id-type="pmid">33831942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r148">
          <label>148</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome.</article-title>
            <source>BMC Urol</source>
            <year>2020</year>
            <month>Mar</month>
            <day>30</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <pub-id pub-id-type="pmid">32228552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r149">
          <label>149</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;lp&#x00131;nar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Halilo&#x0011f;lu</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>G&#x000f6;kce</surname>
                <given-names>M&#x00130;</given-names>
              </name>
              <name>
                <surname>Ar&#x00131;kan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Instillation of Hyaluronic Acid via Electromotive Drug Administration Can Improve the Efficacy of Treatment in Patients With Interstitial Cystitis/Painful Bladder Syndrome: A Randomized Prospective Study.</article-title>
            <source>Korean J Urol</source>
            <year>2014</year>
            <month>May</month>
            <volume>55</volume>
            <issue>5</issue>
            <fpage>354</fpage>
            <page-range>354-9</page-range>
            <pub-id pub-id-type="pmid">24868341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r150">
          <label>150</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashemi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malde</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Applications of electromotive drug administration in urology.</article-title>
            <source>Urol Ann</source>
            <year>2020</year>
            <season>Oct-Dec</season>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-308</page-range>
            <pub-id pub-id-type="pmid">33776323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r151">
          <label>151</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome.</article-title>
            <source>Int J Clin Pract</source>
            <year>2013</year>
            <month>May</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>427</fpage>
            <page-range>427-34</page-range>
            <pub-id pub-id-type="pmid">23574103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r152">
          <label>152</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morgado</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Charrua</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>199</volume>
            <issue>4</issue>
            <fpage>998</fpage>
            <page-range>998-1003</page-range>
            <pub-id pub-id-type="pmid">29031769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r153">
          <label>153</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Chancellor</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome.</article-title>
            <source>BJU Int</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>657</fpage>
            <page-range>657-61</page-range>
            <pub-id pub-id-type="pmid">19338543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r154">
          <label>154</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giannantoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gubbiotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bini</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis.</article-title>
            <source>Toxins (Basel)</source>
            <year>2019</year>
            <month>Aug</month>
            <day>30</day>
            <volume>11</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31480323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r155">
          <label>155</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panunzio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tafuri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mazzucato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cerrato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pagliarulo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Antonelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cerruto</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin-A Injection in Chronic Pelvic Pain Syndrome Treatment: A Systematic Review and Pooled Meta-Analysis.</article-title>
            <source>Toxins (Basel)</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>14</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35051002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r156">
          <label>156</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome.</article-title>
            <source>Toxins (Basel)</source>
            <year>2015</year>
            <month>Oct</month>
            <day>22</day>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>4283</fpage>
            <page-range>4283-93</page-range>
            <pub-id pub-id-type="pmid">26506388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r157">
          <label>157</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Modified Botulinum Toxin Type A Injections Improve Symptoms Associated With Interstitial Cystitis/Bladder Pain Syndrome in Women: A Retrospective Cohort Study.</article-title>
            <source>Urology</source>
            <year>2024</year>
            <month>Jul</month>
            <volume>189</volume>
            <fpage>27</fpage>
            <page-range>27-33</page-range>
            <pub-id pub-id-type="pmid">38710455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r158">
          <label>158</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>YC</given-names>
              </name>
            </person-group>
            <article-title>Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>609</fpage>
            <page-range>609-14</page-range>
            <pub-id pub-id-type="pmid">25914337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r159">
          <label>159</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dinis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>189</volume>
            <issue>2</issue>
            <fpage>548</fpage>
            <page-range>548-53</page-range>
            <pub-id pub-id-type="pmid">23253961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r160">
          <label>160</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ogah</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dubos</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Brazzelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Jul</month>
            <day>30</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD013325</fpage>
            <pub-id pub-id-type="pmid">32734597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r161">
          <label>161</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Plair</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hemal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Langefeld</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Badlani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zambon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heath</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Bladder Hydrodistention Does Not Result in a Significant Change in Bladder Capacity for Interstitial Cystitis/Bladder Pain Syndrome Patients.</article-title>
            <source>Urology</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>132</volume>
            <fpage>81</fpage>
            <page-range>81-86</page-range>
            <pub-id pub-id-type="pmid">31299328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r162">
          <label>162</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glemain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rivi&#x000e8;re</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lenormand</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bouchot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Buzelin</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Prolonged hydrodistention of the bladder for symptomatic treatment of interstitial cystitis: efficacy at 6 months and 1 year.</article-title>
            <source>Eur Urol</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-84</page-range>
            <pub-id pub-id-type="pmid">11999471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r163">
          <label>163</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Neuromodulation for the treatment of refractory interstitial cystitis.</article-title>
            <source>Rev Urol</source>
            <year>2002</year>
            <volume>4 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S36</fpage>
            <page-range>S36-43</page-range>
            <pub-id pub-id-type="pmid">16986033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r164">
          <label>164</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sacral Neuromodulation for Refractory Bladder Pain Syndrome/Interstitial Cystitis: a Global Systematic Review and Meta-analysis.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Sep</month>
            <day>08</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>11031</fpage>
            <pub-id pub-id-type="pmid">28887515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r165">
          <label>165</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baaklini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hassani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abolella</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Safwat</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Neudecker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hijaz</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>El-Nashar</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Sacral neuromodulation treating chronic pelvic pain: a meta-analysis and systematic review of the literature.</article-title>
            <source>Int Urogynecol J</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>1023</fpage>
            <page-range>1023-1035</page-range>
            <pub-id pub-id-type="pmid">30874835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r166">
          <label>166</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>TX</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Is Urethrectomy Necessary During Cystectomy in Patients With Interstitial Cystitis or Bladder Pain Syndrome?</article-title>
            <source>Urology</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>97</volume>
            <fpage>73</fpage>
            <page-range>73-79</page-range>
            <pub-id pub-id-type="pmid">27424120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r167">
          <label>167</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costello</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Supratrigonal cystectomy and ileocystoplasty in management of interstitial cystitis.</article-title>
            <source>Aust N Z J Surg</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-8</page-range>
            <pub-id pub-id-type="pmid">10696940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r168">
          <label>168</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of augmentation ileocystoplasty combined with supratrigonal cystectomy for the treatment of refractory bladder pain syndrome/interstitial cystitis with Hunner's lesion.</article-title>
            <source>Int J Urol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>21 Suppl 1</volume>
            <fpage>69</fpage>
            <page-range>69-73</page-range>
            <pub-id pub-id-type="pmid">24807503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r169">
          <label>169</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madec</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Hedhli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Perrouin-Verbe</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Levesque</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Normand</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rigaud</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Feasibility, Morbidity, and Functional Results of Supratrigonal Cystectomy with Augmentation Ileocystoplasty by Combined Robot-Assisted Laparoscopy and Mini-Laparotomy Approach.</article-title>
            <source>J Endourol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>655</fpage>
            <page-range>655-660</page-range>
            <pub-id pub-id-type="pmid">28467725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r170">
          <label>170</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Queissert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bruecher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Ophoven</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schrader</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Supratrigonal cystectomy and augmentation cystoplasty with ileum or ileocecum in the treatment of ulcerative interstitial cystitis/bladder pain syndrome: a 14-year follow-up.</article-title>
            <source>Int Urogynecol J</source>
            <year>2022</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>1267</fpage>
            <page-range>1267-1272</page-range>
            <pub-id pub-id-type="pmid">35230481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r171">
          <label>171</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osman</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Bratt</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Esperto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chapple</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review of Surgical interventions for the Treatment of Bladder Pain Syndrome/Interstitial Cystitis.</article-title>
            <source>Eur Urol Focus</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>877</fpage>
            <page-range>877-885</page-range>
            <pub-id pub-id-type="pmid">32127327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r172">
          <label>172</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mykoniatis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tsiakaras</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Samarinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anastasiadis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Symeonidis</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Sountoulides</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis.</article-title>
            <source>Biologics</source>
            <year>2022</year>
            <volume>16</volume>
            <fpage>47</fpage>
            <page-range>47-55</page-range>
            <pub-id pub-id-type="pmid">35619987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r173">
          <label>173</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kocat&#x000fc;rk</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Atasoy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bedir</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Altay</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Demird&#x000f6;&#x0011f;en</surname>
                <given-names>&#x0015e;O</given-names>
              </name>
              <name>
                <surname>Ko&#x000e7;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Questionnaire-guided evaluation of the effectiveness of long-term intravesical 0.2% chondroitin sulfate therapy in interstitial cystitis.</article-title>
            <source>Int Urogynecol J</source>
            <year>2021</year>
            <month>May</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>1293</fpage>
            <page-range>1293-1298</page-range>
            <pub-id pub-id-type="pmid">32047969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r174">
          <label>174</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danacioglu</surname>
                <given-names>YO</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ozkanli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yildirim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Silay</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Caskurlu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Intravesical Hyaluronic Acid, Chondroitin Sulfate, and Combination of Hyaluronic Acid-Chondroitin Sulfate Therapies in Animal Model of Interstitial Cystitis.</article-title>
            <source>Int Neurourol J</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-50</page-range>
            <pub-id pub-id-type="pmid">33504136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r175">
          <label>175</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;zk&#x00131;d&#x00131;k</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Assessment of long-term intravesical hyaluronic acid, chondroitin sulfate and combination therapy for patients with bladder pain syndrome.</article-title>
            <source>Cent European J Urol</source>
            <year>2019</year>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>270</fpage>
            <page-range>270-275</page-range>
            <pub-id pub-id-type="pmid">31720029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r176">
          <label>176</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stellavato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pirozzi</surname>
                <given-names>AVA</given-names>
              </name>
              <name>
                <surname>Diana</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fusco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Donnarumma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schiraldi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>e0218475</fpage>
            <pub-id pub-id-type="pmid">31237905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r177">
          <label>177</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma.</article-title>
            <source>Biomedicines</source>
            <year>2022</year>
            <month>May</month>
            <day>20</day>
            <volume>10</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">35625918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r178">
          <label>178</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallego-Vilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Fadrique</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Povo-Martin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Salvador-Marin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gallego-Gomez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Maintenance of the response to dimethyl sulfoxide treatment using hyperbaric oxygen in interstitial cystitis/painful bladder syndrome: a prospective, randomized, comparative study.</article-title>
            <source>Urol Int</source>
            <year>2013</year>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>411</fpage>
            <page-range>411-6</page-range>
            <pub-id pub-id-type="pmid">23485788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r179">
          <label>179</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chuang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome.</article-title>
            <source>J Urol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>182</volume>
            <issue>4</issue>
            <fpage>1393</fpage>
            <page-range>1393-400</page-range>
            <pub-id pub-id-type="pmid">19683290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r180">
          <label>180</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyagi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Majima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawamorita</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoshizawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Intravesical liposome therapy for interstitial cystitis.</article-title>
            <source>Int J Urol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>262</fpage>
            <page-range>262-271</page-range>
            <pub-id pub-id-type="pmid">28258657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r181">
          <label>181</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome.</article-title>
            <source>J Cell Mol Med</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>624</fpage>
            <page-range>624-635</page-range>
            <pub-id pub-id-type="pmid">34953040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r182">
          <label>182</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Etulain</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Platelets in wound healing and regenerative medicine.</article-title>
            <source>Platelets</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>556</fpage>
            <page-range>556-568</page-range>
            <pub-id pub-id-type="pmid">29442539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r183">
          <label>183</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mussano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Genova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Munaron</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Petrillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erovigni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carossa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cytokine, chemokine, and growth factor profile of platelet-rich plasma.</article-title>
            <source>Platelets</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>467</fpage>
            <page-range>467-71</page-range>
            <pub-id pub-id-type="pmid">26950533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r184">
          <label>184</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuffler</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Platelet-rich plasma and the elimination of neuropathic pain.</article-title>
            <source>Mol Neurobiol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>315</fpage>
            <page-range>315-32</page-range>
            <pub-id pub-id-type="pmid">23832571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r185">
          <label>185</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study.</article-title>
            <source>Low Urin Tract Symptoms</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>O42</fpage>
            <page-range>O42-O47</page-range>
            <pub-id pub-id-type="pmid">29265766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r186">
          <label>186</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>703</fpage>
            <page-range>703-709</page-range>
            <pub-id pub-id-type="pmid">30576011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r187">
          <label>187</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Sep</month>
            <day>16</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>15218</fpage>
            <pub-id pub-id-type="pmid">32939046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r188">
          <label>188</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Birder</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection.</article-title>
            <source>Int Neurourol J</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>Suppl 1</issue>
            <fpage>S57</fpage>
            <page-range>S57-67</page-range>
            <pub-id pub-id-type="pmid">35073671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r189">
          <label>189</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ke</surname>
                <given-names>QS</given-names>
              </name>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency.</article-title>
            <source>Ci Ji Yi Xue Za Zhi</source>
            <year>2019</year>
            <season>Jul-Sep</season>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-143</page-range>
            <pub-id pub-id-type="pmid">31258287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r190">
          <label>190</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Treatment with low-energy shock wave alleviates pain in an animal model of uroplakin 3A-induced autoimmune interstitial cystitis/painful bladder syndrome.</article-title>
            <source>Investig Clin Urol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>359</fpage>
            <page-range>359-366</page-range>
            <pub-id pub-id-type="pmid">31501798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r191">
          <label>191</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment.</article-title>
            <source>Biomedicines</source>
            <year>2022</year>
            <month>Feb</month>
            <day>07</day>
            <volume>10</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35203604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r192">
          <label>192</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>200</volume>
            <issue>3</issue>
            <fpage>590</fpage>
            <page-range>590-596</page-range>
            <pub-id pub-id-type="pmid">29653163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r193">
          <label>193</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Campian</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>FF</given-names>
              </name>
            </person-group>
            <article-title>Interstitial Cystitis/Bladder Pain Syndrome.</article-title>
            <source>Semin Reprod Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-135</page-range>
            <pub-id pub-id-type="pmid">30566978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r194">
          <label>194</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cvach</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rosamilia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Review of intravesical therapies for bladder pain syndrome/interstitial cystitis.</article-title>
            <source>Transl Androl Urol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>629</fpage>
            <page-range>629-37</page-range>
            <pub-id pub-id-type="pmid">26816864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r195">
          <label>195</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradley</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gallop</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sutcliffe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kreder</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Naliboff</surname>
                <given-names>BD</given-names>
              </name>
              <collab>Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network</collab>
            </person-group>
            <article-title>Long-Term Symptom Trajectories in Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study.</article-title>
            <source>Urology</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>169</volume>
            <fpage>58</fpage>
            <page-range>58-64</page-range>
            <pub-id pub-id-type="pmid">35961564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r196">
          <label>196</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Engelsgjerd</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Deibert</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <chapter-title>Cystoscopy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">29630232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r197">
          <label>197</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Axiotakis</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Youngerman</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Casals</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Boyett</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lalwani</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>McKhann</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Risk of Acquiring Perioperative COVID-19 During the Initial Pandemic Peak: A Retrospective Cohort Study.</article-title>
            <source>Ann Surg</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>273</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-48</page-range>
            <pub-id pub-id-type="pmid">33156061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r198">
          <label>198</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottschalk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Aken</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zenz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Standl</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Is anesthesia dangerous?</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>108</volume>
            <issue>27</issue>
            <fpage>469</fpage>
            <page-range>469-74</page-range>
            <pub-id pub-id-type="pmid">21814522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r199">
          <label>199</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fasting</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Risk in anaesthesia].</article-title>
            <source>Tidsskr Nor Laegeforen</source>
            <year>2010</year>
            <month>Mar</month>
            <day>11</day>
            <volume>130</volume>
            <issue>5</issue>
            <fpage>498</fpage>
            <page-range>498-502</page-range>
            <pub-id pub-id-type="pmid">20224619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r200">
          <label>200</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breau</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Assessing self-help issues for patients with prostate cancer, interstitial cystitis, erectile dysfunction and urinary diversion.</article-title>
            <source>BJU Int</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>92</volume>
            <issue>7</issue>
            <fpage>736</fpage>
            <page-range>736-40</page-range>
            <pub-id pub-id-type="pmid">14616457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r201">
          <label>201</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gohritz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dellon</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Bladder Pain Syndome/Interstitial Cystitis due to Pudendal Nerve Compression: Described in 1915-A Reminder for Treating Pelvic Pain a Century Later.</article-title>
            <source>J Brachial Plex Peripher Nerve Inj</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>e5</fpage>
            <page-range>e5-e8</page-range>
            <pub-id pub-id-type="pmid">32153650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r202">
          <label>202</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korting</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>161</volume>
            <issue>2</issue>
            <fpage>558</fpage>
            <page-range>558-65</page-range>
            <pub-id pub-id-type="pmid">9915448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r203">
          <label>203</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Graziottin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Felice</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gambini</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Alpha Lipoic Acid Plus Omega-3 Fatty Acids for Vestibulodynia Associated With Painful Bladder Syndrome.</article-title>
            <source>J Obstet Gynaecol Can</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>131</fpage>
            <page-range>131-137</page-range>
            <pub-id pub-id-type="pmid">28343553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r204">
          <label>204</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Tucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Feliciantonio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vena</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Capone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schiavi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pietrangeli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Muzii</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Benedetti Panici</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Alpha lipoic acid in obstetrics and gynecology.</article-title>
            <source>Gynecol Endocrinol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>729</fpage>
            <page-range>729-733</page-range>
            <pub-id pub-id-type="pmid">29726290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r205">
          <label>205</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katske</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shoskes</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sender</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poliakin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gagliano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of interstitial cystitis with a quercetin supplement.</article-title>
            <source>Tech Urol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-6</page-range>
            <pub-id pub-id-type="pmid">11272677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r206">
          <label>206</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bologna</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gomelsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lukban</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Holzberg</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Whitmore</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of calcium glycerophosphate in the prevention of food-related flares in interstitial cystitis.</article-title>
            <source>Urology</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6 Suppl 1</issue>
            <fpage>119</fpage>
            <page-range>119-20</page-range>
            <pub-id pub-id-type="pmid">11378102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132252.r207">
          <label>207</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gaines</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sirls</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care.</article-title>
            <source>Transl Androl Urol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>611</fpage>
            <page-range>611-9</page-range>
            <pub-id pub-id-type="pmid">26816861</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
